<?xml version='1.0' encoding='UTF-8'?>
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="publisher-id">nss</journal-id>
      <journal-title-group>
        <journal-title>Nature and Science of Sleep</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1179-1608</issn>
      <publisher>
        <publisher-name>Dove</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">37621721</article-id>
      <article-id pub-id-type="pmc">10445641</article-id>
      <article-id pub-id-type="publisher-id">412793</article-id>
      <article-id pub-id-type="doi">10.2147/NSS.S412793</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate</article-title>
        <alt-title alt-title-type="running-authors">Schneider et al</alt-title>
        <alt-title alt-title-type="running-title">Schneider et al</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8729-5224</contrib-id>
          <name>
            <surname>Schneider</surname>
            <given-names>Logan D</given-names>
          </name>
          <xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref>
          <xref rid="an0001" ref-type="corresp"/>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4494-0195</contrib-id>
          <name>
            <surname>Morse</surname>
            <given-names>Anne Marie</given-names>
          </name>
          <xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Strunc</surname>
            <given-names>Michael J</given-names>
          </name>
          <xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2710-3133</contrib-id>
          <name>
            <surname>Lee-Iannotti</surname>
            <given-names>Joyce K</given-names>
          </name>
          <xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7043-2974</contrib-id>
          <name>
            <surname>Bogan</surname>
            <given-names>Richard K</given-names>
          </name>
          <xref rid="aff0005" ref-type="aff">
<sup>5</sup>
</xref>
        </contrib>
        <aff id="aff0001"><label>1</label><institution>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine</institution>, <addr-line>Stanford</addr-line>, <addr-line>CA</addr-line>, <country>USA</country></aff>
        <aff id="aff0002"><label>2</label><institution>Janet Weis Children’s Hospital, Geisinger Medical Center</institution>, <addr-line>Danville</addr-line>, <addr-line>PA</addr-line>, <country>USA</country></aff>
        <aff id="aff0003"><label>3</label><institution>The Center for Pediatric Sleep Medicine, Children’s Hospital of The King’s Daughters</institution>, <addr-line>Norfolk</addr-line>, <addr-line>VA</addr-line>, <country>USA</country></aff>
        <aff id="aff0004"><label>4</label><institution>Department of Neurology, The University of Arizona College of Medicine</institution>, <addr-line>Phoenix</addr-line>, <addr-line>AZ</addr-line>, <country>USA</country></aff>
        <aff id="aff0005"><label>5</label><institution>Department of Pulmonology, University of South Carolina School of Medicine</institution>, <addr-line>Columbia</addr-line>, <addr-line>SC</addr-line>, <country>USA</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="an0001">Correspondence: Logan D Schneider, <institution>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine</institution>, <addr-line>450 Broadway St, Pavilion C 2nd Fl MC 5704</addr-line>, <addr-line>Redwood City</addr-line>, <addr-line>CA</addr-line>, <addr-line>94063</addr-line>, <country>USA</country>, <phone>Tel +1 650 723-6601</phone>, <fax>Fax +1 650 721-3448</fax>, Email logands@gmail.com</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>19</day>
        <month>8</month>
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2023</year>
      </pub-date>
      <volume>15</volume>
      <fpage>663</fpage>
      <lpage>675</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>3</month>
          <year>2023</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2023 Schneider et al.</copyright-statement>
        <copyright-year>2023</copyright-year>
        <copyright-holder>Schneider et al.</copyright-holder>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref>
          <license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Abstract</title>
        <p><citation_analysis attribute="positive">Narcolepsy and idiopathic hypersomnia are chronic conditions that negatively affect alertness, mental and physical energy, functioning, and quality of life (QoL). Calcium, magnesium, potassium, and sodium oxybates (low-sodium oxybate; LXB) is an oxybate formulation with 92% less sodium than sodium oxybate (SXB; a treatment for narcolepsy) and the same active moiety. LXB is approved in the US for treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age or older with narcolepsy, and idiopathic hypersomnia in adults. In Phase 3 clinical trials, LXB exhibited a safety profile consistent with that of SXB in narcolepsy. Besides continued efficacy in treating symptoms, potential benefits of long-term LXB treatment include flexible optimization of dosing and regimen, improvement of QoL and functioning, weight loss, and (relative to SXB in narcolepsy) health benefits of reduced sodium content. Dosing of LXB is twice nightly (for narcolepsy) or once or twice nightly (for idiopathic hypersomnia) based on patient characteristics and response, and individualized titration can be leveraged over the long term as a patient’s life circumstances change. Patients with narcolepsy transitioning from SXB initiate LXB at the same dose, and most patients require no further changes to achieve similar efficacy and tolerability. Improvements in functioning and QoL with LXB treatment could have cascading positive effects in multiple domains, particularly in younger patients. In clinical trials, LXB was associated with weight loss in both narcolepsy (in which obesity is a well-established comorbidity) and idiopathic hypersomnia, only occasionally leading participants to be underweight. As both narcolepsy and idiopathic hypersomnia are associated with increased risk of cardiometabolic and cardiovascular comorbidities, limiting medication-related sodium intake with LXB may have significant health benefits, although this has not yet been verified prospectively due to the prolonged follow-up required. LXB is a promising long-term treatment for narcolepsy and idiopathic hypersomnia.</citation_analysis></p>
      </abstract>
      <abstract abstract-type="video">
        <title>Video abstract</title>
        <p><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><fig position="anchor" id="uf0001" fig-type="figure"><graphic xlink:href="NSS-15-663-g0001" content-type="print-only" position="float"/></fig></citation_analysis><citation_analysis attribute="positive">
</citation_analysis></p>
        <p><citation_analysis attribute="neither">Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use:</citation_analysis></p>
        <p><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><underline>
<ext-link xlink:href="https://youtu.be/7ZOAk26V35M" ext-link-type="uri">https://youtu.be/7ZOAk26V35M</ext-link>
</underline></citation_analysis><citation_analysis attribute="positive">
</citation_analysis></p>
      </abstract>
      <abstract abstract-type="plain-language-summary">
        <title>Plain Language Summary</title>
        <p><citation_analysis attribute="negative">Narcolepsy and idiopathic hypersomnia are disorders that make people feel very sleepy. Low-sodium oxybate (LXB) is a medicine for these disorders. Doctors think LXB works on parts of the brain that keep people awake. LXB may quiet those brain parts down at night by reducing their electrical activity, which helps people sleep better. LXB wears off by the morning, so people can wake up normally and feel more alert the next day. LXB has less sodium (which is part of salt) than a medicine called sodium oxybate. Sodium oxybate has been used for narcolepsy for more than 20 years. LXB has several benefits. First, LXB may be healthier than medicines that contain a lot of sodium, such as a high-sodium oxybate. This is because sodium can increase blood pressure and risk of heart disease. Second, LXB can be taken twice each night for narcolepsy, or once or twice each night for idiopathic hypersomnia. This depends on a person’s lifestyle, how well the medicine is working, and side effects. Third, people taking LXB are more able to work and do other activities and have better quality of life. Finally, people taking LXB may lose weight. This can help overweight or obese people.</citation_analysis></p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <title>Keywords</title>
        <kwd>cardiovascular</kwd>
        <kwd>dosing</kwd>
        <kwd>LXB</kwd>
        <kwd>hypersomnolence</kwd>
        <kwd>quality of life</kwd>
        <kwd>weight loss</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
<institution-wrap><institution>Jazz Pharmaceuticals</institution><institution-id institution-id-type="open-funder-registry">10.13039/100011096</institution-id></institution-wrap>
</funding-source>
        </award-group>
        <funding-statement>Support for the development of this article was funded by Jazz Pharmaceuticals.</funding-statement>
      </funding-group>
      <counts>
        <fig-count count="0"/>
        <ref-count count="121"/>
        <page-count count="13"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s0002">
      <title>Introduction</title>
      <p><citation_analysis attribute="neither">Central disorders of hypersomnolence are a family of disorders characterized by excessive daytime sleepiness (EDS).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="negative"> They include narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2); idiopathic hypersomnia; Kleine-Levin syndrome; insufficient sleep syndrome; and hypersomnia due to a medical disorder, medication or substance, or psychiatric disorder.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> Narcolepsy and idiopathic hypersomnia are chronic and potentially lifelong conditions</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0002" ref-type="bibr">2</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0003" ref-type="bibr">3</xref></citation_analysis><citation_analysis attribute="neither"> that negatively impact alertness, mental and physical energy, functioning, and quality of life (QoL).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0004" ref-type="bibr">4</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0005" ref-type="bibr">5</xref></citation_analysis><citation_analysis attribute="neither"> Both are underrecognized and underdiagnosed.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis><citation_analysis attribute="neither"> Treatment options are generally limited and symptoms targeted due, in part, to incomplete understanding of their pathophysiology.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0002" ref-type="bibr">2</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Calcium, magnesium, potassium, and sodium oxybates (low-sodium oxybate; LXB; Xywav</citation_analysis><citation_analysis attribute="positive"><sup>®</sup></citation_analysis><citation_analysis attribute="neither">) was developed to meet evolving health-care needs, with 8% of the sodium content of sodium oxybate (SXB), and approved by the US Food and Drug Administration (FDA) in 2020 for the treatment of cataplexy or EDS in patients 7 years of age or older with narcolepsy.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0008" ref-type="bibr">8–12</xref></citation_analysis><citation_analysis attribute="neither"> LXB is also effective in idiopathic hypersomnia, a therapeutic area with no other current FDA-approved treatments, and was approved by the US FDA in 2021 for the treatment of idiopathic hypersomnia in adults—the first medication to be indicated for the treatment of the entire disorder, rather than its individual symptoms (ie, EDS).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0008" ref-type="bibr">8</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">The purpose of this paper is to discuss the impact and potential benefits of long-term LXB treatment in narcolepsy and idiopathic hypersomnia.</citation_analysis></p>
      <sec id="s0002-s2001">
        <title>Narcolepsy and Idiopathic Hypersomnia: Presentation and Lifelong Burden</title>
        <p><citation_analysis attribute="neither">Narcolepsy is associated with a pentad of symptoms, including EDS, cataplexy, hypnagogic/hypnopompic hallucinations, sleep paralysis, and disrupted nighttime sleep (DNS).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0013" ref-type="bibr">13</xref></citation_analysis><citation_analysis attribute="neither"> EDS is a defining characteristic of both NT1 and NT2. Cataplexy is often present in NT1 but is always absent in NT2.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> The onset of narcolepsy symptoms typically occurs during the teen years, with a potential second peak of onset in the mid-30s.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0014" ref-type="bibr">14</xref></citation_analysis><citation_analysis attribute="neither"> Symptoms evolve over a period of years; EDS is usually the first to appear, followed by cataplexy (in NT1), and then other symptoms.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> NT1 is a stable, lifelong disorder, whereas NT2 may spontaneously remit.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15–19</xref></citation_analysis><citation_analysis attribute="neither"> The prevalence of narcolepsy in 2016 was estimated at 44.3 per 100,000 persons.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis><citation_analysis attribute="neither"> In association with the sleep/wake state instability and EDS of narcolepsy, the following are common: decreased functioning and ability to pursue activities,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0004" ref-type="bibr">4</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0020" ref-type="bibr">20–22</xref></citation_analysis><citation_analysis attribute="neither"> decreased QoL,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0004" ref-type="bibr">4</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0005" ref-type="bibr">5</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0024" ref-type="bibr">24</xref></citation_analysis><citation_analysis attribute="neither"> increased usage of medical resources and associated health-care costs,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0025" ref-type="bibr">25</xref></citation_analysis><citation_analysis attribute="neither"> and reduced productivity and increased associated costs (eg, short-term disability incidents and days).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0025" ref-type="bibr">25</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">Idiopathic hypersomnia is also characterized by EDS,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> but in contrast to narcolepsy, patients emphasize virtually continuous cognitive aspects of EDS (eg, impaired alertness and difficulty sustaining attention; “brain fog”) as being especially burdensome.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0026" ref-type="bibr">26</xref></citation_analysis><citation_analysis attribute="neither"> Cataplexy is absent.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> Associated features include severe, prolonged sleep inertia (defined as “prolonged difficulty waking up with repeated returns to sleep, irritability, automatic behavior, and confusion”) and long (&gt;1 hr) unrefreshing naps.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> Long sleep time (≥11 hr in a 24-hr period) may be present but is not necessary for diagnosis and may also be seen in narcolepsy.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0027" ref-type="bibr">27</xref></citation_analysis><citation_analysis attribute="neither"> Symptom onset is typically in the late teens or early 20s but may occur earlier.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0028" ref-type="bibr">28–30</xref></citation_analysis><citation_analysis attribute="neither"> Symptoms may be long-lasting or spontaneously remit.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0016" ref-type="bibr">16</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0017" ref-type="bibr">17</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0028" ref-type="bibr">28</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither"> The prevalence of idiopathic hypersomnia in 2016 was estimated at 10.3 per 100,000 persons.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7</xref></citation_analysis><citation_analysis attribute="neither"> Idiopathic hypersomnia is associated with decreased functioning, inability to pursue typical life activities, and poorer QoL.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0004" ref-type="bibr">4</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0005" ref-type="bibr">5</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0031" ref-type="bibr">31</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis></p>
      </sec>
      <sec id="s0002-s2002">
        <title>Diagnosis of Narcolepsy and Idiopathic Hypersomnia</title>
        <p><citation_analysis attribute="neither">Diagnosis of narcolepsy and idiopathic hypersomnia may be delayed by 10 years or more after symptom onset.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0033" ref-type="bibr">33</xref></citation_analysis><citation_analysis attribute="neither"> Diagnoses of other disorders, including psychiatric disorders, attention deficit/hyperactivity disorder (ADHD), other sleep disorders, and epilepsy,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither"> are common and contribute to delays in receiving optimal care.</citation_analysis></p>
        <p><citation_analysis attribute="neither">Upon review of the </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">International Classification of Sleep Disorders</italic></citation_analysis><citation_analysis attribute="positive">, 3rd Edition (ICSD-3) diagnostic criteria for narcolepsy (NT1 and NT2) and idiopathic hypersomnia, it is apparent that there is considerable overlap of diagnostic criteria, particularly between NT2 and idiopathic hypersomnia, for which findings on the multiple sleep latency test (MSLT) are the only clearly differentiating diagnostic criterion:</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0017" ref-type="bibr">17</xref></citation_analysis><citation_analysis attribute="neither"> At least two sleep onset rapid eye movement periods (SOREMPs) are required for a diagnosis of NT2, and exclude an idiopathic hypersomnia diagnosis.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> However, there are additional differences in associated characteristics, such as the frequent presence (idiopathic hypersomnia) vs typical absence (NT2) of sleep inertia, nonrestorative naps (idiopathic hypersomnia) vs restorative naps (NT2), and less prevalent REM dissociative symptoms in idiopathic hypersomnia compared with NT2.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="positive"> Similarities among the disorders represent a significant diagnostic challenge.</citation_analysis></p>
        <p><citation_analysis attribute="neither">A defined protocol for diagnostic testing is lacking. Evaluation begins with clinical examination and history, aiming to narrow the list of possible diagnoses. Of the three disorders considered here, NT1 may be the easiest to identify if cataplexy is present, but other differential diagnoses need to be considered as well. Diagnostic testing (eg, polysomnography, actigraphy, and MSLT) is necessary to confirm a diagnosis according to the ICSD-3 criteria. Hypocretin levels in cerebrospinal fluid may be obtained (eg, for diagnosis of NT1 in the absence of cataplexy), but there is no official guidance regarding when and under what circumstances to measure these levels. The potential for misdiagnosis is considerable since several psychiatric comorbidities (eg, mood disorders) and other medical or behavioral conditions (eg, substance abuse) are associated with hypersomnolence.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> In pediatric patients, presentation of EDS and cataplexy in narcolepsy or idiopathic hypersomnia can mimic symptoms of ADHD, epilepsy, or psychotic disorders,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither"> and differentiation of excessive sleep due to idiopathic hypersomnia versus non-pathologic, age-appropriate long sleep duration can be difficult.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> In response to these challenges, a new classification of sleep disorders, based on differently defined clinical characteristics and with less emphasis on MSLT results because of its limited sensitivity and specificity in this context, has been proposed.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0035" ref-type="bibr">35</xref></citation_analysis><citation_analysis attribute="neither"> This classification includes three diagnostic categories: narcolepsy, idiopathic hypersomnia, and idiopathic excessive sleepiness.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0035" ref-type="bibr">35</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">Comorbidities associated with NT1, NT2, and idiopathic hypersomnia are wide-ranging, and many are overlapping. Obesity is a well-established comorbidity of narcolepsy,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0021" ref-type="bibr">21</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0036" ref-type="bibr">36</xref></citation_analysis><citation_analysis attribute="positive"> estimated in the Burden of Narcolepsy Disease (BOND) study to be 2 to 3 times more likely in people with narcolepsy compared with non-narcolepsy controls (odds ratio [OR]: 2.3 [95% confidence interval, CI: 2.2 to 2.5]; </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">&lt;0.0001).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0037" ref-type="bibr">37</xref></citation_analysis><citation_analysis attribute="negative"> The BOND study also identified an increased risk of cardiometabolic and cardiovascular (CV) conditions and events, including diabetes (OR [95% CI]: 1.8 [1.7, 1.8]; </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">&lt;0.0001), stroke (2.5 [2.3, 2.7]; </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">&lt;0.0001), myocardial infarction (1.6 [1.3, 1.8]; </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">&lt;0.0001), cardiac arrest (1.6 [1.1, 2.3]; </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P=</italic></citation_analysis><citation_analysis attribute="neither">0.0326), and heart failure (2.6 [2.3, 2.9]; </citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="positive">&lt;0.0001). These findings were verified more recently, in general, in the Cardiovascular Burden of Narcolepsy Disease (CV-BOND) study.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0038" ref-type="bibr">38</xref></citation_analysis><citation_analysis attribute="neither"> Finally, there is a significantly elevated prevalence of headache/migraine; psychiatric conditions, including anxiety disorders and mood disorders; and other sleep disorders, including periodic limb movement disorder (PLMD), sleep apnea, rapid eye movement (REM), sleep behavior disorder (RBD), and restless legs syndrome (RLS).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0037" ref-type="bibr">37</xref></citation_analysis><citation_analysis attribute="neither"> In a survey, many people with narcolepsy specified that they had comorbid psychiatric and sleep disorders (eg, depression [32.0–35.3%] and anxiety disorder [25.7–27.5%]) that had been correctly diagnosed, as opposed to having been misdiagnosed.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither"> Idiopathic hypersomnia does not seem to be associated with obesity, but a retrospective claims analysis identified diabetes, hyperlipidemia, psychiatric disorders (mood, depressive, and anxiety disorders), and other sleep disorders (sleep apnea, PLMD, RLS, RBD) as common comorbidities.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis><citation_analysis attribute="neither"> CV conditions or events, including hypertension, major adverse cardiac event, atrial fibrillation, heart failure, and stroke, were also found to be common.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis><citation_analysis attribute="neither"> Finally, headache/migraine is common,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis><citation_analysis attribute="neither"> and autonomic dysfunction and cognitive symptoms relating to memory and attention have been reported.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0040" ref-type="bibr">40</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0041" ref-type="bibr">41</xref></citation_analysis></p>
      </sec>
      <sec id="s0002-s2003">
        <title>Treatment of Narcolepsy and Idiopathic Hypersomnia</title>
        <p><citation_analysis attribute="neither">Treatment of narcolepsy and idiopathic hypersomnia involves a whole-patient, multifactorial approach. Both nonpharmacologic and pharmacologic interventions should be incorporated, guided by the patient’s individual circumstances, such as symptom profile and lifestyle (eg, parents of young children; women of childbearing potential). Nonpharmacologic interventions include lifestyle modifications and preventive therapy focusing on factors such as sleep hygiene (eg, discontinuation of electronics use well before bedtime), adjustment of work hours (eg, beginning work later in the day rather than early morning), regular exercise, and a healthy diet.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0042" ref-type="bibr">42–44</xref></citation_analysis><citation_analysis attribute="neither"> In addition, cognitive behavioral therapy for hypersomnia emphasizes education about the disease state, self-identity and self-image (including strategies for self-acceptance), structured daytime and nighttime activities, coping skills and emotional regulation, social support, and medical/legal/occupational issues (eg, potential accommodations).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0045" ref-type="bibr">45</xref></citation_analysis><citation_analysis attribute="neither"> As far as pharmacologic approaches, narcolepsy and idiopathic hypersomnia are often treated off-label, and treatment is generally symptomatic (eg, EDS and cataplexy) due to poor understanding of the pathophysiology of NT2 and idiopathic hypersomnia. The pathophysiology of NT1, as related to hypocretin deficiency, is clearer.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0046" ref-type="bibr">46</xref></citation_analysis><citation_analysis attribute="neither"> Approved pharmacologic agents commonly utilized in narcolepsy include oxybate (LXB [only indicated in the US], SXB, and recently fixed-dose, high-sodium oxybate),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0047" ref-type="bibr">47</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0048" ref-type="bibr">48</xref></citation_analysis><citation_analysis attribute="neither"> wake-promoting agents (eg, modafinil, armodafinil, solriamfetol, and pitolisant), and stimulants (eg, methylphenidate and dextroamphetamine). Antidepressants (eg, venlafaxine, clomipramine, and fluoxetine) are often used off-label. Currently, LXB is the only approved treatment for idiopathic hypersomnia in the US.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> Modafinil was previously approved in the EU, but the approval was rescinded in 2011.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0049" ref-type="bibr">49</xref></citation_analysis><citation_analysis attribute="neither"> Off-label treatments for idiopathic hypersomnia include modafinil, stimulants (methylphenidate, amphetamines, and mazindol), clarithromycin, and pitolisant. Treatment guidelines provide recommendations for use of these agents.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0050" ref-type="bibr">50</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0051" ref-type="bibr">51</xref></citation_analysis><citation_analysis attribute="neither"> Most of the pharmacologic therapies employed in central disorders of hypersomnolence have not undergone rigorous clinical trials or head-to-head studies. However, pivotal clinical trials of LXB have recently been conducted, supporting its use in both narcolepsy (NT1 and NT2)</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis><citation_analysis attribute="neither"> and idiopathic hypersomnia.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0053" ref-type="bibr">53</xref></citation_analysis></p>
      </sec>
      <sec id="s0002-s2004">
        <title>Development and Characterization of LXB</title>
        <p><citation_analysis attribute="neither">SXB is a standard of care, based on American Academy of Sleep Medicine and French consensus guidelines, for the treatment of EDS and cataplexy in narcolepsy.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0050" ref-type="bibr">50</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0051" ref-type="bibr">51</xref></citation_analysis><citation_analysis attribute="neither"> However, at the recommended dosage range for adults (6–9 g/night), SXB contributes 1100 mg to 1640 mg to daily sodium intake.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0054" ref-type="bibr">54</xref></citation_analysis><citation_analysis attribute="neither"> The recommended upper limit of daily sodium intake in adults is 2000 mg/day to 2300 mg/day,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0055" ref-type="bibr">55–60</xref></citation_analysis><citation_analysis attribute="neither"> but for many people, dietary sodium intake exceeds this limit (mean for Americans aged 2–19 years in 2013–2014: 3033 mg/day).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0061" ref-type="bibr">61</xref></citation_analysis><citation_analysis attribute="neither"> Thus, treatment with SXB adds to sodium intake that may already be excessive. It is well established that excess sodium intake is associated with increased blood pressure and CV risk.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0062" ref-type="bibr">62–65</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">LXB is a multiple-cation formulation of oxybate that contains 92% less sodium than SXB, with the same active moiety, at the same concentration, gram for gram.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0008" ref-type="bibr">8</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> In pharmacokinetic/pharmacodynamic (PK/PD) studies in healthy adults, LXB had lower maximum plasma drug concentration compared with SXB (C</citation_analysis><citation_analysis attribute="positive"><sub>max</sub></citation_analysis><citation_analysis attribute="neither">: arithmetic mean, 101.8 vs 135.7 µg/mL), delayed time to C</citation_analysis><citation_analysis attribute="positive"><sub>max</sub></citation_analysis><citation_analysis attribute="neither"> (T</citation_analysis><citation_analysis attribute="positive"><sub>max:</sub></citation_analysis><citation_analysis attribute="neither"> median, 0.75 vs 0.50 h), and similar area under the plasma concentration–time curve (AUC</citation_analysis><citation_analysis attribute="positive"><sub>0-t</sub></citation_analysis><citation_analysis attribute="neither">: arithmetic mean, 235.4 vs 263.9 μg∙h/mL; AUC</citation_analysis><citation_analysis attribute="positive"><sub>0-∞</sub></citation_analysis><citation_analysis attribute="neither">: arithmetic mean, 236.5 vs 265.2 μg∙h/mL) in the fasted state at equivalent oxybate doses.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0066" ref-type="bibr">66</xref></citation_analysis><citation_analysis attribute="neither"> Bioequivalence of LXB and SXB, under fasted conditions, was to be declared if the 90% CIs for the ratio of geometric least-squares means of log-transformed AUC</citation_analysis><citation_analysis attribute="positive"><sub>0-t</sub></citation_analysis><citation_analysis attribute="neither">, AUC</citation_analysis><citation_analysis attribute="positive"><sub>0-∞</sub></citation_analysis><citation_analysis attribute="neither">, and C</citation_analysis><citation_analysis attribute="positive"><sub>max</sub></citation_analysis><citation_analysis attribute="neither"> were all contained within 80% and 125%. As the criteria were met for AUC but not C</citation_analysis><citation_analysis attribute="positive"><sub>max</sub></citation_analysis><citation_analysis attribute="neither">, LXB and SXB were found to be not bioequivalent.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0066" ref-type="bibr">66</xref></citation_analysis><citation_analysis attribute="neither"> An additional finding was that C</citation_analysis><citation_analysis attribute="positive"><sub>max</sub></citation_analysis><citation_analysis attribute="neither"> and AUC of LXB were lower under fed than fasted conditions.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0066" ref-type="bibr">66</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">The mechanism of action of oxybate (gamma-hydroxybutyrate; GHB) in the treatment of narcolepsy and idiopathic hypersomnia is unknown,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> in part due to the incomplete understanding of the pathophysiology of these disorders.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> Hypocretin deficiency is a key element of NT1, and NT2 may involve partial hypocretin/orexin deficiency severe enough to cause sleepiness but not cataplexy,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> although this is controversial.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0067" ref-type="bibr">67</xref></citation_analysis><citation_analysis attribute="neither"> The pathophysiology of idiopathic hypersomnia remains unknown; no deficiency in hypocretin-1 has been observed.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> Since GHB is an endogenous brain neurotransmitter that acts at GHB-specific receptors and gamma-aminobutyric acid B (GABA</citation_analysis><citation_analysis attribute="positive"><sub>B</sub></citation_analysis><citation_analysis attribute="neither">) receptors,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0068" ref-type="bibr">68</xref></citation_analysis><citation_analysis attribute="positive"> it is hypothesized that the therapeutic effects of oxybate on EDS and cataplexy are mediated through GABA</citation_analysis><citation_analysis attribute="positive"><sub>B</sub></citation_analysis><citation_analysis attribute="neither"> actions at dopaminergic and noradrenergic neurons, as well as at thalamocortical neurons, during sleep.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">Because bioequivalence criteria were not met in PK/PD studies,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0066" ref-type="bibr">66</xref></citation_analysis><citation_analysis attribute="neither"> a phase 3 clinical trial of LXB in narcolepsy (NCT03030599) was conducted in 2017–2019.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0008" ref-type="bibr">8</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis><citation_analysis attribute="positive"> Overall, the results of this LXB study are broadly consistent with SXB in narcolepsy, with a similar efficacy and safety profile.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0069" ref-type="bibr">69–75</xref></citation_analysis><citation_analysis attribute="neither"> A study of LXB in idiopathic hypersomnia (NCT03533114) was conducted concurrently, in 2018–2020.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0053" ref-type="bibr">53</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">The narcolepsy pivotal trial of LXB was a multicenter, double-blind, placebo-controlled, randomized withdrawal study in adults with narcolepsy with cataplexy.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis><citation_analysis attribute="positive"> Participants entered an open-label optimized treatment and titration period (OLOTTP; 12 weeks), followed by a stable-dose period (SDP; 2 weeks), and then a double-blind randomized withdrawal period (DBRWP; 2 weeks). An optional open-label extension (OLE) followed the DBRWP. The duration of the study was 16 weeks (main study) or 40 weeks (including the OLE). A total of 201 participants were enrolled and treated in the OLOTTP, and 149 participants entered the SDP (74.1% retention rate). The primary endpoint was met: There was a significant worsening in the weekly number of cataplexy attacks from the end of the SDP to the end of the DBRWP in the placebo group, compared with no change in the LXB group (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">&lt;0.0001). On the key secondary endpoint, scores on the Epworth Sleepiness Scale (ESS) significantly worsened from the end of the SDP to the end of the DBRWP in the placebo group and did not change in the LXB group (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="positive">&lt;0.0001). On other secondary endpoints, LXB demonstrated improvement compared with placebo on overall narcolepsy symptom severity, QoL, and self-assessed current health status. In post hoc analyses, LXB was found to reduce cataplexy frequency and increase cataplexy-free days per week during the OLOTTP and SDP.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0076" ref-type="bibr">76</xref></citation_analysis><citation_analysis attribute="neither"> Changes in cataplexy frequency observed during OLOTTP differed by cataplexy treatment at study entry, but cataplexy-free days were high in all groups at the end of the SDP.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0076" ref-type="bibr">76</xref></citation_analysis><citation_analysis attribute="positive"> Efficacy of LXB during the OLE was not measured in this trial. Improvements in DNS were not tested for LXB but were previously demonstrated for SXB, which were associated with beneficial effects on sleep architecture, including increases in non-rapid eye movement (NREM) sleep, stages 3 and 4 sleep, and delta power, and decreases in awakenings, REM sleep, stage 1 sleep, and stage shifts.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0077" ref-type="bibr">77–79</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">Treatment-emergent adverse events (TEAEs) were common (reported by 76.1% while receiving LXB during the main study) and consistent with those seen in studies of SXB.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0069" ref-type="bibr">69</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0072" ref-type="bibr">72</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0074" ref-type="bibr">74</xref></citation_analysis><citation_analysis attribute="positive"> TEAEs resulting in LXB discontinuation during the main study (11.9% overall) were worsening cataplexy (3.5%), nausea (1.5%), and anxiety, depressed mood, depression, headache, and irritability (each 1.0%). Serious TEAEs were reported by 6 participants, and TEAEs considered related to study medication were reported by two participants (confusion and hallucinations in one participant after accidental deviation from usual interval between doses; muscle enzyme increased in one participant after intense activity). Similar to prior long-term safety results with SXB in narcolepsy,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0071" ref-type="bibr">71</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0080" ref-type="bibr">80</xref></citation_analysis><citation_analysis attribute="positive"> the long-term safety and tolerability profiles of LXB during the OLE were generally consistent with those during the main study.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0081" ref-type="bibr">81</xref></citation_analysis><citation_analysis attribute="neither"> TEAEs were most prevalent early in the OLE and declined thereafter.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0081" ref-type="bibr">81</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">The idiopathic hypersomnia pivotal trial of LXB was a multicenter, double-blind, placebo-controlled, randomized withdrawal study in adults with idiopathic hypersomnia.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0053" ref-type="bibr">53</xref></citation_analysis><citation_analysis attribute="neither"> Similar to the narcolepsy study, participants entered an initial open-label titration and optimization period (called OLT in this study; 10–14 weeks), followed by an SDP (2 weeks) and a DBRWP (2 weeks). A required OLE (24 weeks) followed the DBRWP. The duration of the study was 38 to 42 weeks. A total of 154 participants were enrolled and treated in the OLT, and 123 participants entered the SDP (79.9% retention rate). The primary endpoint was met: ESS scores worsened from the end of the SDP to the end of the DBRWP in the placebo group and remained stable in the LXB group (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">&lt;0.0001). In post hoc analyses, this effect was similar in subgroups of participants defined by sex, age, long sleep phenotype (ie, with or without long sleep), and baseline treatment (taking baseline idiopathic hypersomnia medication or treatment naive). On key secondary endpoints, Idiopathic Hypersomnia Severity Scale (IHSS) total scores increased (indicating worsening) from the end of the SDP to the end of the DBRWP in the placebo group and remained stable in the LXB group (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="neither">&lt;0.0001), and the proportion of participants reporting worsening in symptoms on the Patient Global Impression of Change (PGIc) at the end of the DBRWP relative to the end of the SDP was greater with placebo compared with LXB (</citation_analysis><citation_analysis attribute="positive"><italic toggle="yes">P</italic></citation_analysis><citation_analysis attribute="positive">&lt;0.0001). On other secondary and exploratory endpoints, LXB demonstrated improvement compared with placebo on the Clinical Global Impression of Change, functional outcomes, sleep inertia, work productivity, and activity impairment. In post hoc analyses, scores on several of these measures improved during open-label LXB treatment in the OLT and SDP</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0082" ref-type="bibr">82</xref></citation_analysis><citation_analysis attribute="neither"> and were maintained long term over the 24-week OLE.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0083" ref-type="bibr">83</xref></citation_analysis><citation_analysis attribute="positive"> TEAEs were reported by 80% of participants overall and were consistent with those seen in the LXB study in narcolepsy.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0053" ref-type="bibr">53</xref></citation_analysis><citation_analysis attribute="neither"> TEAEs leading to discontinuation occurred in 17% of participants while receiving LXB. Four participants experienced nine serious TEAEs; none were related to study drug.</citation_analysis></p>
        <p><citation_analysis attribute="neither">The FDA approved LXB for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy in July 2020, and for the treatment of idiopathic hypersomnia in adults in August 2021.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> The approval of LXB for the treatment of narcolepsy in pediatric patients is based on clinical trial data of SXB in pediatric participants 7 to 17 years of age with narcolepsy,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0075" ref-type="bibr">75</xref></citation_analysis><citation_analysis attribute="positive"> the similar treatment effects with LXB and SXB in clinical studies in adults with narcolepsy, PK data from studies of SXB in adult and pediatric participants, and PK data from studies of LXB in adults.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> LXB is not approved outside of the US.</citation_analysis></p>
      </sec>
      <sec id="s0002-s2005">
        <title>Benefits of Long-Term Treatment with LXB</title>
        <p><citation_analysis attribute="neither">There are no randomized controlled studies comparing LXB with other treatment options. LXB efficacy/tolerability is similar or superior to SXB for most patients with narcolepsy, although there are some patients who prefer SXB.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0084" ref-type="bibr">84</xref></citation_analysis><citation_analysis attribute="neither"> LXB is newly approved, and clinical trials of ~1 year in duration are available for narcolepsy and idiopathic hypersomnia;</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0053" ref-type="bibr">53</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0076" ref-type="bibr">76</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0082" ref-type="bibr">82</xref></citation_analysis><citation_analysis attribute="neither"> for narcolepsy, there is also a well-established, 20-year history of SXB usage supporting certain benefits of oxybate treatment, including individualized optimization of dosing and regimen, improvement of QoL and functioning, and association with weight loss. LXB also has the benefit of reduced sodium content.</citation_analysis></p>
        <sec id="s0002-s2005-s3001">
          <title>Individualized Optimization of Dosing and Regimen</title>
          <p><citation_analysis attribute="neither">For narcolepsy, LXB dosing is twice nightly (symmetric or asymmetric), and titration is as needed (for those transitioning from SXB) or occurs in increments of up to 1.5 g/night/week.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> Twice-nightly doses are separated by 2.5 to 4 hr.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> A clear understanding of PK and PD will enhance dosing adjustments and improve drug efficacy and safety, particularly when administered with knowledge of circadian entrainment. For idiopathic hypersomnia, dosing is once or twice nightly, and titration occurs in increments of up to 1.5 g/night/week.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> The recommended LXB dosing interval is based on its PK profile (peak exposure [C</citation_analysis><citation_analysis attribute="positive"><sub>max</sub></citation_analysis><citation_analysis attribute="neither">] within 1 hr and decay within 4 hr</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0066" ref-type="bibr">66</xref></citation_analysis><citation_analysis attribute="neither">). Once-nightly dosing or asymmetric twice-nightly dosing may be preferable based on individual patient circumstances (eg, single dosing in idiopathic hypersomnia if there is difficulty awakening during the night for a second dose, or asymmetric dosing in either disorder if there is awakening during the night after a single dose but difficulty waking up in the morning after an equal second dose).</citation_analysis></p>
          <p><citation_analysis attribute="neither">For patients transitioning from SXB, LXB is initiated at the same dose and regimen.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="positive"> In an interim analysis of a Phase 4, open-label study (SEGUE), 90.5% of participants with narcolepsy reported that the process of transitioning was easy. In the phase 3 study of LXB in narcolepsy, most (50/55; 90.9%) participants who entered taking SXB achieved a stable total nightly dose of LXB within 1 titration step (range: 0–8).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0076" ref-type="bibr">76</xref></citation_analysis><citation_analysis attribute="neither"> Sixteen (29.1%) required an increase in dose (maximum increase: 4.25 g/night), whereas 2 (3.6%) decreased their dose (by ≤1.5 g/night).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0076" ref-type="bibr">76</xref></citation_analysis><citation_analysis attribute="neither"> Hence, while most patients can transition from SXB to LXB with no change in dose, others require a change for similar efficacy.</citation_analysis></p>
        </sec>
        <sec id="s0002-s2005-s3002">
          <title>Improvement of QoL and Functioning</title>
          <p><citation_analysis attribute="positive">A strength of LXB clinical studies is the use of multiple endpoints assessing not only symptoms but also consequences, such as impairment of QoL and/or functioning. LXB demonstrated efficacy on QoL and/or functioning (which in itself can be considered a measure of QoL) in both narcolepsy and idiopathic hypersomnia, as described earlier (measured using the SF-36 [narcolepsy] and FOSQ-10 and WPAI:SHP [idiopathic hypersomnia]).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0053" ref-type="bibr">53</xref></citation_analysis><citation_analysis attribute="positive"> Functioning was not assessed in clinical studies of LXB in narcolepsy. In idiopathic hypersomnia, few other agents have demonstrated benefits on functioning, limited mostly to improvement in driving ability.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0085" ref-type="bibr">85</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0086" ref-type="bibr">86</xref></citation_analysis><citation_analysis attribute="positive"> Improvement in quality of wakefulness and functioning may have a broad impact on a person’s life, including in the longer term as new opportunities arise that might not otherwise have been possible. For example, patients whose ability to work was limited as a result of idiopathic hypersomnia</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0032" ref-type="bibr">32</xref></citation_analysis><citation_analysis attribute="positive"> and whose functioning improved with LXB treatment might experience an impact not only on their immediate employment prospects but also on their overall career trajectory. This could have cascading effects in other domains.</citation_analysis></p>
          <sec id="s0002-s2005-s3002-s4001">
            <title>Weight Loss</title>
            <p><citation_analysis attribute="neither">In the LXB clinical trials, treatment during the open-label periods was associated with weight loss, similar to SXB.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0087" ref-type="bibr">87</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0088" ref-type="bibr">88</xref></citation_analysis><citation_analysis attribute="neither"> In the study of LXB in narcolepsy,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0089" ref-type="bibr">89</xref></citation_analysis><citation_analysis attribute="positive"> 31.8% and 35.3% of participants were overweight or obese, respectively, at study entry, consistent with the well-established increased risk of obesity in narcolepsy.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0021" ref-type="bibr">21</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0036" ref-type="bibr">36</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0037" ref-type="bibr">37</xref></citation_analysis><citation_analysis attribute="neither"> At the end of the SDP, with a total of 14 weeks of LXB treatment, mean (SD) change in body weight in the overall population was −1.6 (3.5) kg.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0089" ref-type="bibr">89</xref></citation_analysis><citation_analysis attribute="neither"> Mean weight loss was numerically greater in oxybate-naive participants compared with participants who had been taking SXB at study entry; among oxybate-naive participants, mean weight loss was also numerically greater in participants who were overweight or obese compared with normal weight. Most (91%) normal weight participants remained normal weight, 15% of overweight participants became normal weight, and 8% of obese participants became overweight. A single TEAE of decreased weight was reported.</citation_analysis></p>
            <p><citation_analysis attribute="neither">Results in the study of LXB in idiopathic hypersomnia were similar,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0090" ref-type="bibr">90</xref></citation_analysis><citation_analysis attribute="neither"> although, as noted earlier, idiopathic hypersomnia is not strongly associated with obesity.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0039" ref-type="bibr">39</xref></citation_analysis><citation_analysis attribute="positive"> At study entry, 33.8% and 24.7% of participants were overweight or obese, respectively. At the end of the SDP, mean (SD) change in body weight in the overall population was −2.5 (4.1) kg. Mean weight loss was numerically greater in overweight or obese versus normal weight participants. Weight loss was substantial (≥5%) in 28.7% of participants. Most (92.1%) of normal weight participants remained normal weight, 16.7% of overweight participants became normal weight, and 12.1% of obese participants became overweight. TEAEs of decreased weight were reported by 5 (3.2%) participants.</citation_analysis></p>
            <p><citation_analysis attribute="neither">The mechanism by which LXB leads to weight loss is unknown. For SXB, which is also associated with weight loss,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0087" ref-type="bibr">87</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0088" ref-type="bibr">88</xref></citation_analysis><citation_analysis attribute="neither"> proposed mechanisms of weight loss include increased physical activity, normalization of hormone secretion (eg, growth hormone, leptin, and/or thyroid-stimulating hormone), and stimulation of metabolism and lipolysis.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0087" ref-type="bibr">87</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0091" ref-type="bibr">91</xref></citation_analysis><citation_analysis attribute="positive"> In people previously treated with SXB, LXB might also be associated with reduced fluid retention as a result of its lower sodium content.</citation_analysis></p>
          </sec>
          <sec id="s0002-s2005-s3002-s4002">
            <title>Reduced Sodium Intake</title>
            <p><citation_analysis attribute="neither">Sleep disorders and excess sodium intake are each associated with increased CV risk. Narcolepsy and idiopathic hypersomnia are associated with cardiometabolic and CV comorbidities and events,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0037" ref-type="bibr">37–39</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0092" ref-type="bibr">92</xref></citation_analysis><citation_analysis attribute="positive"> and people with narcolepsy are more likely than healthy controls to demonstrate nocturnal non-dipping blood pressure,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0093" ref-type="bibr">93</xref></citation_analysis><citation_analysis attribute="negative"> which is itself a predictor of CV risk and mortality in the general population.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0094" ref-type="bibr">94–96</xref></citation_analysis><citation_analysis attribute="neither"> The mechanisms underlying the link between sleep disorders (and poor sleep or EDS in general</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0097" ref-type="bibr">97</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0098" ref-type="bibr">98</xref></citation_analysis><citation_analysis attribute="negative">) and CV risk are poorly understood, but NT1 may be related to hypocretin deficiency and associated dysregulation of the sympathetic nervous system.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0099" ref-type="bibr">99</xref></citation_analysis></p>
            <p><citation_analysis attribute="positive">The modest sodium load associated with LXB, compared with SXB, is likely to be beneficial for the health of people with narcolepsy or idiopathic hypersomnia, including young people. As these are chronic disorders that are often diagnosed in a period spanning adolescence to early adulthood,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0030" ref-type="bibr">30</xref></citation_analysis><citation_analysis attribute="negative"> providers should be cognizant of any long-term health consequences of the chosen treatment, even in patients who are young and appear otherwise healthy. Evidence indicates that presence of CV risk factors early in life may be predictive of poorer outcomes in adulthood. For example, a population-based longitudinal study in 38,589 participants found that hypertension and obesity in children were associated with a significantly increased risk of fatal or nonfatal CV events before the age of 60 years.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0100" ref-type="bibr">100</xref></citation_analysis></p>
            <p><citation_analysis attribute="neither">Reduction in sodium intake is associated with decreased CV risk,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0101" ref-type="bibr">101–107</xref></citation_analysis><citation_analysis attribute="neither"> and high sodium-containing medications are associated with increased CV risk.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0108" ref-type="bibr">108–111</xref></citation_analysis><citation_analysis attribute="positive"> LXB has been recognized by the US FDA in the narcolepsy population for its significant reduction in chronic sodium burden compared with SXB, which “will be clinically meaningful in reducing cardiovascular morbidity in a substantial proportion of patients for whom the drug is indicated.”</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0112" ref-type="bibr">112</xref></citation_analysis><citation_analysis attribute="positive"> While this has not yet been verified prospectively due to the long-term follow-up required, the potential benefit of reduced sodium intake with LXB is inferred based on the literature on sodium intake, blood pressure, and CV health. However, it is notable that, in the LXB narcolepsy study, mean systolic blood pressure values and prevalence of CV/cardiometabolic comorbidities were higher in participants taking SXB at study entry, compared with participants who were not.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0076" ref-type="bibr">76</xref></citation_analysis><citation_analysis attribute="neither"> Concomitant use of stimulants and wake-promoting agents, which could also have been associated with higher blood pressure, was common in the same study whether or not participants were taking SXB at baseline (groups by treatment at study entry: SXB only, 67.3%; SXB + other anticataplectics, 60.9%; other anticataplectics, 77.8%; anticataplectic naive, 48.9%).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0113" ref-type="bibr">113</xref></citation_analysis><citation_analysis attribute="positive"> Finally, it is important to note that excessive sodium intake is only one element of larger cardiovascular, cardiometabolic, and cardiorenal management issues, and reduced sodium intake may not be positive for every patient (eg, in people with orthostatic hypotension, the higher sodium content in SXB may be beneficial). The American Heart Association has identified eight essential measures for improving and maintaining cardiovascular health, including diet as one component; others include monitoring and management of cardiovascular/cardiometabolic indicators (cholesterol, blood glucose, and blood pressure) and other lifestyle changes (exercise, cessation of nicotine use, weight management, and adequate sleep).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0114" ref-type="bibr">114</xref></citation_analysis></p>
          </sec>
        </sec>
      </sec>
      <sec id="s0002-s2006">
        <title>Perspectives and Clinical Practice Considerations</title>
        <p><citation_analysis attribute="neither">Selection of the appropriate therapy for each patient is based on a number of considerations. Confidence in the diagnosis of narcolepsy or idiopathic hypersomnia is paramount, as LXB is not indicated for other sleep disorders. LXB may not be appropriate for all patients (eg, some parents of young children), and individual circumstances should be considered (eg, profession, wake time, history of psychiatric issues or substance abuse). Patients with long histories of depression or anxiety, with or without suicide attempts, may have worsening depression after initiating LXB and should be monitored.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> Conversely, however, improvement in depressive symptoms as measured with the Patient Health Questionnaire-9 was observed in the phase 3 study of LXB in narcolepsy.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">Misuse of illicitly produced and acquired GHB (the same active ingredient as in SXB and LXB) has been noted, potentially due to its anxiolytic, hypnotic, and euphoric effects.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0068" ref-type="bibr">68</xref></citation_analysis><citation_analysis attribute="neither"> In patients with a history of substance abuse, the potential for misuse or abuse of prescription oxybate therapy may be a barrier, but not necessarily always.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="neither"> SXB has been available in the US through a long-running, restricted-distribution Risk Evaluation and Mitigation Strategy (REMS) program, which has also been applied to LXB since its approval.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0115" ref-type="bibr">115</xref></citation_analysis><citation_analysis attribute="positive"> The REMS program incorporates a number of safeguards to prevent abuse, misuse, and diversion, and historical data have demonstrated that controlled access to SXB was rigorously maintained.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0115" ref-type="bibr">115</xref></citation_analysis><citation_analysis attribute="neither"> Furthermore, LXB is not unique in having concerns of this type; other treatments with known potential for abuse and/or diversion (eg, methylphenidate</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0116" ref-type="bibr">116</xref></citation_analysis><citation_analysis attribute="neither">) are widely used in the treatment of hypersomnia.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0050" ref-type="bibr">50</xref></citation_analysis></p>
        <p><citation_analysis attribute="positive">It is essential to ensure that patients with narcolepsy and idiopathic hypersomnia are treated optimally, focusing on addressing the debilitating and potentially hazardous symptoms of EDS and cataplexy in narcolepsy, and symptoms in idiopathic hypersomnia including (but not restricted to) EDS. Early, effective treatment may have significant benefits, as treatment of children and adolescents forms part of a continuum of care over the course of a potentially lifelong disease. Any effective treatment beginning during childhood/adolescence (a period of significant neuroplasticity) might actually alter the disease course, although this is speculative; in contrast, delayed treatment beginning during adulthood might be limited to management of symptoms after years of dysfunction. The potential cascading impact of treatment benefits on QoL and functioning, as described earlier, may be especially impactful in younger patients.</citation_analysis></p>
        <p><citation_analysis attribute="neither">Strategies to improve treatment success include proactive and ongoing titration of LXB dosing and regimen to maximize efficacy and tolerability. A patient’s optimal dose and regimen may change over time as the patient ages or individual circumstances evolve. Following that evolution with regular follow-up and monitoring with tools such as those used as endpoints in clinical trials may be helpful and complementary to discussions surrounding QoL.</citation_analysis></p>
      </sec>
    </sec>
    <sec id="s0003">
      <title>Future Research</title>
      <p><citation_analysis attribute="positive">Future research should address knowledge gaps related to LXB and to the disorders of narcolepsy and idiopathic hypersomnia. Real-world evidence is presently sparse but should be available soon, as results from OLEs, phase 4 trials (including the SEGUE study mentioned earlier), and other studies are published. The mechanism of action of LXB, similar to SXB, is largely unknown;</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0009" ref-type="bibr">9</xref></citation_analysis><citation_analysis attribute="positive"> improved understanding may emerge from preclinical studies. A better understanding of the sleep effects of LXB and correlation with outcomes in narcolepsy and idiopathic hypersomnia may contribute to improved understanding of the mechanism of action of LXB and open possibilities for its use in other sleep disorders. Finally, the potential impact of LXB treatment on future disease course and comorbid medical conditions should be explored in prospectively monitored, population-level/epidemiologic datasets, such as claims databases). Brain structural and functional changes have been demonstrated in narcolepsy and idiopathic hypersomnia,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0117" ref-type="bibr">117–120</xref></citation_analysis><citation_analysis attribute="neither"> as in obstructive sleep apnea,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0121" ref-type="bibr">121</xref></citation_analysis><citation_analysis attribute="negative"> and it would be of interest to explore possible neuroprotection with LXB treatment. A related issue is the impact of LXB, hypocretin deficiency, and other disease aspects in future risk of comorbidities.</citation_analysis></p>
    </sec>
    <sec id="s0004">
      <title>Conclusion</title>
      <p><citation_analysis attribute="positive">LXB is a promising long-term treatment for narcolepsy and idiopathic hypersomnia, demonstrating efficacy on symptoms including EDS, cataplexy, and sleep inertia, with a safety profile consistent with that of SXB in narcolepsy. Individualized treatment involving titration of dosage/regimen can be leveraged over the long term to maximize efficacy and tolerability as a patient’s life circumstances change. Improvements in functioning and QoL could have cascading positive effects in multiple domains, particularly in younger patients. Weight loss in people who are overweight or obese may have long-term health benefits, particularly as obesity is a well-established comorbidity of narcolepsy. Limiting medication-related sodium intake with LXB may have significant health benefits, especially in relation to decreased risk of cardiovascular morbidity.</citation_analysis></p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p><citation_analysis attribute="neither">At the direction of the authors, Karyn Liu, PhD, and Michael J. Theisen, PhD, of Peloton Advantage, LLC, an OPEN Health company, provided medical writing and editorial support, which was funded by Jazz Pharmaceuticals.</citation_analysis></p>
    </ack>
    <sec id="s0005">
      <title>Abbreviations</title>
      <p><citation_analysis attribute="neither">ADHD, attention deficit/hyperactivity disorder; AUC, area under the plasma concentration–time curve; BMI, body mass index; BOND, Burden of Narcolepsy Disease; CGIc, Clinical Global Impression of Change; CI, confidence interval; CV, cardiovascular; C</citation_analysis><citation_analysis attribute="positive"><sub>max</sub></citation_analysis><citation_analysis attribute="neither">, maximum plasma drug concentration; DNS, disrupted nighttime sleep; DBRWP, double-blind randomized withdrawal period; EDS, excessive daytime sleepiness; ESS, Epworth Sleepiness Scale; FDA, Food and Drug Administration; FOSQ-10, Functional Outcomes of Sleep Questionnaire, short version; GABA</citation_analysis><citation_analysis attribute="positive"><sub>B</sub></citation_analysis><citation_analysis attribute="neither">, gamma-aminobutyric acid B; GHB, gamma-hydroxybutyrate; ICSD-3, International Classification of Sleep Disorders, 3rd Edition; IH, idiopathic hypersomnia; IHSS, Idiopathic Hypersomnia Severity Scale; IQR, interquartile range; LSM, least squares mean; LXB, low-sodium oxybate; MCS, Mental Component Summary; MSLT, Multiple Sleep Latency Test; NT1, narcolepsy type 1; NT2, narcolepsy type 2; OLE, open-label extension; OLOTTP, open-label optimized treatment and titration period; OLT, open-label titration and optimization period; PCS, Physical Component Summary; PD, pharmacodynamic; PGIc, Patient Global Impression of Change; PK, pharmacokinetic; PLMD, periodic limb movement disorder; QoL, quality of life; RBD, REM sleep behavior disorder; REM, rapid eye movement; REMS, Risk Evaluation and Mitigation Strategy; RLS, restless legs syndrome; SD, standard deviation; SDP, stable-dose period; SE, standard error; SF-36, 36-item Short-Form Survey; SOREMP, sleep onset rapid eye movement period; SXB, high-sodium oxybate; TEAE, treatment-emergent adverse event; T</citation_analysis><citation_analysis attribute="positive"><sub>max</sub></citation_analysis><citation_analysis attribute="neither">, time to C</citation_analysis><citation_analysis attribute="positive"><sub>max</sub></citation_analysis><citation_analysis attribute="neither">; VAS, visual analog scale; VAS-SI, visual analog scale for sleep inertia; WPAI:SHP, Work Productivity and Activity Impairment Questionnaire: Specific Health Problem.</citation_analysis></p>
    </sec>
    <sec id="s0006">
      <title>Author Contributions</title>
      <p><citation_analysis attribute="positive">All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.</citation_analysis></p>
    </sec>
    <sec sec-type="COI-statement" id="s0007">
      <title>Disclosure</title>
      <p><citation_analysis attribute="neither">Logan D. Schneider is a compensated member of advisory boards and speakers bureaus for Jazz Pharmaceuticals, Eisai, and Harmony Biosciences. Anne Marie Morse has received research/grant support and consultancy fees from Avadel, Geisinger Health Plan, ResMed Foundation, Harmony Biosciences, Jazz Pharmaceuticals, Takeda Pharmaceutical Co., Ltd, NLS Pharmaceuticals, Alkermes, UCB Pharmaceuticals, and NIH. She is also a paid expert consultant of Irish State Claims Agency; CEO of DAMM Good Sleep, LLC. Michael J. Strunc has participated in advisory boards for Jazz Pharmaceuticals. Joyce K. Lee-Iannotti has no conflicts of interest to disclose. Richard K. Bogan is a shareholder of Watermark Medical and Healthy Humming, LLC; serves on the board of directors for Watermark; is a medical consultant to Jazz Pharmaceuticals, Harmony Biosciences, Avadel Pharmaceuticals, Takeda, and Oventus; has conducted industry-funded research for Avadel, Axsome, Bresotec, Bayer, Idorsia, Suven, Jazz, Balance, NLS, Vanda, Merck, Eisai, Philips, Fresca, Takeda, LivaNova, Roche, Sanofi, Sommetrics, and Noctrix; and is on the speakers bureau for Jazz, Eisai, and Harmony.</citation_analysis></p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="cit0001">
        <label>1.</label>
        <mixed-citation publication-type="book"><collab>American Academy of Sleep Medicine</collab>. <source><italic toggle="yes">International Classification of Sleep Disorders – Third Edition,Text Revision (ICSD-3-TR)</italic></source>. <publisher-loc>Darien, IL</publisher-loc>: <publisher-name>American Academy of Sleep Medicine</publisher-name>; <year>2023</year>.</mixed-citation>
      </ref>
      <ref id="cit0002">
        <label>2.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Barateau</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lopez</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>. <article-title>Treatment options for narcolepsy</article-title>. <source><italic toggle="yes">CNS Drugs</italic></source>. <year>2016</year>;<volume>30</volume>(<issue>5</issue>):<fpage>369</fpage>–<lpage>379</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40263-016-0337-4</pub-id><pub-id pub-id-type="pmid">27155860</pub-id></mixed-citation>
      </ref>
      <ref id="cit0003">
        <label>3.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Billiard</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sonka</surname>
<given-names>K</given-names></string-name>. <article-title>Idiopathic hypersomnia</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2016</year>;<volume>29</volume>:<fpage>23</fpage>–<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2015.08.007</pub-id><pub-id pub-id-type="pmid">26599679</pub-id></mixed-citation>
      </ref>
      <ref id="cit0004">
        <label>4.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wasling</surname>
<given-names>HB</given-names></string-name>, <string-name><surname>Bornstein</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wasling</surname>
<given-names>P</given-names></string-name>. <article-title>Quality of life and procrastination in post-H1N1 narcolepsy, sporadic narcolepsy and idiopathic hypersomnia, a Swedish cross-sectional study</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2020</year>;<volume>76</volume>:<fpage>104</fpage>–<lpage>112</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2020.10.014</pub-id><pub-id pub-id-type="pmid">33152582</pub-id></mixed-citation>
      </ref>
      <ref id="cit0005">
        <label>5.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ozaki</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Inoue</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Nakajima</surname>
<given-names>T</given-names></string-name>, et al. <article-title>Health-related quality of life among drug-naive patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2008</year>;<volume>4</volume>(<issue>6</issue>):<fpage>572</fpage>–<lpage>578</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.27352</pub-id><pub-id pub-id-type="pmid">19110887</pub-id></mixed-citation>
      </ref>
      <ref id="cit0006">
        <label>6.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Thorpy</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Krieger</surname>
<given-names>AC</given-names></string-name>. <article-title>Delayed diagnosis of narcolepsy: characterization and impact</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>5</issue>):<fpage>502</fpage>–<lpage>507</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2014.01.015</pub-id><pub-id pub-id-type="pmid">24780133</pub-id></mixed-citation>
      </ref>
      <ref id="cit0007">
        <label>7.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Acquavella</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Mehra</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Bron</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Suomi</surname>
<given-names>JMH</given-names></string-name>, <string-name><surname>Hess</surname>
<given-names>GP</given-names></string-name>. <article-title>Prevalence of narcolepsy, other sleep disorders, and diagnostic tests from 2013–2016: insured patients actively seeking care</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2020</year>;<volume>16</volume>(<issue>8</issue>):<fpage>1255</fpage>–<lpage>1263</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.8482</pub-id><pub-id pub-id-type="pmid">32807293</pub-id></mixed-citation>
      </ref>
      <ref id="cit0008">
        <label>8.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Junnarkar</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Allphin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Profant</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia</article-title>. <source><italic toggle="yes">Expert Opin Drug Discov</italic></source>. <year>2022</year>;<volume>17</volume>(<issue>2</issue>):<fpage>109</fpage>–<lpage>119</lpage>. doi:<pub-id pub-id-type="doi">10.1080/17460441.2022.1999226</pub-id><pub-id pub-id-type="pmid">34818123</pub-id></mixed-citation>
      </ref>
      <ref id="cit0009">
        <label>9.</label>
        <mixed-citation publication-type="book"><collab><italic toggle="yes">Xywav<sup>®</sup></italic></collab>. <source><italic toggle="yes">(Calcium, Magnesium, Potassium, and Sodium Oxybates) Oral Solution, CIII [Prescribing Information]</italic></source>. <publisher-loc>Palo Alto, CA</publisher-loc>: <publisher-name>Jazz Pharmaceuticals, Inc</publisher-name>; <year>2023</year>.</mixed-citation>
      </ref>
      <ref id="cit0010">
        <label>10.</label>
        <mixed-citation publication-type="webpage"><collab>US Food and Drug Administration</collab>. <article-title>Quantitative labeling of sodium, potassium, and phosphorus for human over-the-counter and prescription drug products</article-title>. <source>Guidance for industry</source>; <year>2022</year>. <comment>Available from</comment>: <ext-link xlink:href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug" ext-link-type="uri">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug</ext-link>. <date-in-citation>Accessed <month>October</month>
<day>11</day>, 2022</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="cit0011">
        <label>11.</label>
        <mixed-citation publication-type="webpage"><collab>US Food and Drug Administration</collab>. <article-title>Clinical review for Binosto, NDA 202344</article-title>; <year>2012</year>. <comment>Available from</comment>: <ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202344Orig1s000MedR.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202344Orig1s000MedR.pdf</ext-link>. <date-in-citation>Accessed <month>February</month>
<day>28</day>, 2023</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="cit0012">
        <label>12.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Szarfman</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kuchenberg</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Soreth</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lajmanovich</surname>
<given-names>S</given-names></string-name>. <article-title>Declaring the sodium content of drug products</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>1995</year>;<volume>333</volume>(<issue>19</issue>):<fpage>1291</fpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM199511093331917</pub-id><pub-id pub-id-type="pmid">7566018</pub-id></mixed-citation>
      </ref>
      <ref id="cit0013">
        <label>13.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Overeem</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Reading</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Bassetti</surname>
<given-names>CL</given-names></string-name>. <article-title>Narcolepsy</article-title>. <source><italic toggle="yes">Sleep Med Clin</italic></source>. <year>2012</year>;<volume>7</volume>:<fpage>263</fpage>–<lpage>281</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsmc.2012.03.013</pub-id></mixed-citation>
      </ref>
      <ref id="cit0014">
        <label>14.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Molinari</surname>
<given-names>N</given-names></string-name>, et al. <article-title>Age at onset of narcolepsy in two large populations of patients in France and Quebec</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2001</year>;<volume>57</volume>(<issue>11</issue>):<fpage>2029</fpage>–<lpage>2033</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.57.11.2029</pub-id><pub-id pub-id-type="pmid">11739821</pub-id></mixed-citation>
      </ref>
      <ref id="cit0015">
        <label>15.</label>
        <mixed-citation publication-type="book"><collab>American Academy of Sleep Medicine</collab>. <source><italic toggle="yes">International Classification of Sleep Disorders</italic></source>. <edition>3rd</edition> ed. <publisher-loc>Darien, IL</publisher-loc>: <publisher-name>American Academy of Sleep Medicine</publisher-name>; <year>2014</year>.</mixed-citation>
      </ref>
      <ref id="cit0016">
        <label>16.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lopez</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Doukkali</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Barateau</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Test-retest reliability of the multiple sleep latency test in central disorders of hypersomnolence</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2017</year>;<volume>40</volume>(<issue>12</issue>). doi:<pub-id pub-id-type="doi">10.1093/sleep/zsx164</pub-id></mixed-citation>
      </ref>
      <ref id="cit0017">
        <label>17.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Trotti</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Staab</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>Rye</surname>
<given-names>DB</given-names></string-name>. <article-title>Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2013</year>;<volume>9</volume>(<issue>8</issue>):<fpage>789</fpage>–<lpage>795</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.2922</pub-id><pub-id pub-id-type="pmid">23946709</pub-id></mixed-citation>
      </ref>
      <ref id="cit0018">
        <label>18.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ruoff</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pizza</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Trotti</surname>
<given-names>LM</given-names></string-name>, et al. <article-title>The MSLT is repeatable in narcolepsy type 1 but not narcolepsy type 2: a retrospective patient study</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2018</year>;<volume>14</volume>(<issue>1</issue>):<fpage>65</fpage>–<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.6882</pub-id><pub-id pub-id-type="pmid">29198301</pub-id></mixed-citation>
      </ref>
      <ref id="cit0019">
        <label>19.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kim</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>CS</given-names></string-name>, <string-name><surname>Yoon</surname>
<given-names>IY</given-names></string-name>. <article-title>Different fates of excessive daytime sleepiness: survival analysis for remission</article-title>. <source><italic toggle="yes">Acta Neurol Scand</italic></source>. <year>2016</year>;<volume>134</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>41</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ane.12504</pub-id><pub-id pub-id-type="pmid">26392230</pub-id></mixed-citation>
      </ref>
      <ref id="cit0020">
        <label>20.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Beusterien</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Rogers</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>Walsleben</surname>
<given-names>JA</given-names></string-name>, et al. <article-title>Health-related quality of life effects of modafinil for treatment of narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>1999</year>;<volume>22</volume>(<issue>6</issue>):<fpage>757</fpage>–<lpage>765</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/22.6.757</pub-id><pub-id pub-id-type="pmid">10505821</pub-id></mixed-citation>
      </ref>
      <ref id="cit0021">
        <label>21.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Mutti</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Brunetti</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Figorilli</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix<sup>®</sup> Cohort</article-title>. <source><italic toggle="yes">Neurol Sci</italic></source>. <year>2022</year>;<volume>43</volume>(<issue>9</issue>):<fpage>5563</fpage>–<lpage>5574</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10072-022-06210-9</pub-id><pub-id pub-id-type="pmid">35750949</pub-id></mixed-citation>
      </ref>
      <ref id="cit0022">
        <label>22.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Davidson</surname>
<given-names>RD</given-names></string-name>, <string-name><surname>Biddle</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Nassan</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Scammell</surname>
<given-names>TE</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>ES</given-names></string-name>. <article-title>The impact of narcolepsy on social relationships in young adults</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2022</year>;<volume>18</volume>(<issue>12</issue>):<fpage>2751</fpage>–<lpage>2761</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.10212</pub-id><pub-id pub-id-type="pmid">35946418</pub-id></mixed-citation>
      </ref>
      <ref id="cit0023">
        <label>23.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Vignatelli</surname>
<given-names>L</given-names></string-name>, <string-name><surname>D’Alessandro</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Mosconi</surname>
<given-names>P</given-names></string-name>, et al. <article-title>Health-related quality of life in Italian patients with narcolepsy: the SF-36 health survey</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2004</year>;<volume>5</volume>(<issue>5</issue>):<fpage>467</fpage>–<lpage>475</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2004.04.003</pub-id><pub-id pub-id-type="pmid">15341892</pub-id></mixed-citation>
      </ref>
      <ref id="cit0024">
        <label>24.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Rovere</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Rossini</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Reimao</surname>
<given-names>R</given-names></string-name>. <article-title>Quality of life in patients with narcolepsy: a WHOQOL-bref study</article-title>. <source><italic toggle="yes">Arq Neuropsiquiatr</italic></source>. <year>2008</year>;<volume>66</volume>(<issue>2a</issue>):<fpage>163</fpage>–<lpage>167</lpage>. doi:<pub-id pub-id-type="doi">10.1590/S0004-282X2008000200004</pub-id><pub-id pub-id-type="pmid">18545775</pub-id></mixed-citation>
      </ref>
      <ref id="cit0025">
        <label>25.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Black</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Reaven</surname>
<given-names>NL</given-names></string-name>, <string-name><surname>Funk</surname>
<given-names>SE</given-names></string-name>, et al. <article-title>The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>5</issue>):<fpage>522</fpage>–<lpage>529</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2014.02.001</pub-id><pub-id pub-id-type="pmid">24768358</pub-id></mixed-citation>
      </ref>
      <ref id="cit0026">
        <label>26.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fronczek</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Arnulf</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Baumann</surname>
<given-names>CR</given-names></string-name>, <string-name><surname>Maski</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Pizza</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Trotti</surname>
<given-names>LM</given-names></string-name>. <article-title>To split or to lump? Classifying the central disorders of hypersomnolence</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2020</year>;<volume>43</volume>(<issue>8</issue>). doi:<pub-id pub-id-type="doi">10.1093/sleep/zsaa044</pub-id></mixed-citation>
      </ref>
      <ref id="cit0027">
        <label>27.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Vernet</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Arnulf</surname>
<given-names>I</given-names></string-name>. <article-title>Narcolepsy with long sleep time: a specific entity?</article-title>
<source><italic toggle="yes">Sleep</italic></source>. <year>2009</year>;<volume>32</volume>(<issue>9</issue>):<fpage>1229</fpage>–<lpage>1235</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/32.9.1229</pub-id><pub-id pub-id-type="pmid">19750928</pub-id></mixed-citation>
      </ref>
      <ref id="cit0028">
        <label>28.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bruck</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Parkes</surname>
<given-names>JD</given-names></string-name>. <article-title>A comparison of idiopathic hypersomnia and narcolepsy-cataplexy using self report measures and sleep diary data</article-title>. <source><italic toggle="yes">J Neurol Neurosurg Psychiatry</italic></source>. <year>1996</year>;<volume>60</volume>(<issue>5</issue>):<fpage>576</fpage>–<lpage>578</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jnnp.60.5.576</pub-id><pub-id pub-id-type="pmid">8778267</pub-id></mixed-citation>
      </ref>
      <ref id="cit0029">
        <label>29.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bassetti</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Aldrich</surname>
<given-names>MS</given-names></string-name>. <article-title>Idiopathic hypersomnia. A series of 42 patients</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>1997</year>;<volume>120</volume>(<issue>8</issue>):<fpage>1423</fpage>–<lpage>1435</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/120.8.1423</pub-id><pub-id pub-id-type="pmid">9278632</pub-id></mixed-citation>
      </ref>
      <ref id="cit0030">
        <label>30.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Anderson</surname>
<given-names>KN</given-names></string-name>, <string-name><surname>Pilsworth</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Sharples</surname>
<given-names>LD</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>IE</given-names></string-name>, <string-name><surname>Shneerson</surname>
<given-names>JM</given-names></string-name>. <article-title>Idiopathic hypersomnia: a study of 77 cases</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2007</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1274</fpage>–<lpage>1281</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/30.10.1274</pub-id><pub-id pub-id-type="pmid">17969461</pub-id></mixed-citation>
      </ref>
      <ref id="cit0031">
        <label>31.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Stevens</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Schneider</surname>
<given-names>LD</given-names></string-name>, <string-name><surname>Husain</surname>
<given-names>AM</given-names></string-name>, et al. <article-title>Impairment in functioning and quality of life in patients with idiopathic hypersomnia: the real world idiopathic hypersomnia outcomes study (ARISE)</article-title>. <source><italic toggle="yes">Nat Sci Sleep</italic></source>. <year>2023</year>;<volume>15</volume>:<fpage>593</fpage>–<lpage>606</lpage>. doi:<pub-id pub-id-type="doi">10.2147/NSS.S396641</pub-id><pub-id pub-id-type="pmid">37551277</pub-id></mixed-citation>
      </ref>
      <ref id="cit0032">
        <label>32.</label>
        <mixed-citation publication-type="confproc"><string-name><surname>Whalen</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Roy</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Steininger</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Dronamraju</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Enson</surname>
<given-names>D</given-names></string-name>. <article-title>Patient perspective on idiopathic hypersomnia: impact on quality of life and satisfaction with the diagnostic process and management [poster 157]</article-title>. <conf-name>Presented at: Annual Meeting of the Associated Professional Sleep Societies</conf-name>; <conf-loc>Charlotte, NC</conf-loc>; <year>2022</year>.</mixed-citation>
      </ref>
      <ref id="cit0033">
        <label>33.</label>
        <mixed-citation publication-type="confproc"><string-name><surname>Whalen</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Roy</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Steininger</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Dronamraju</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Enson</surname>
<given-names>D</given-names></string-name>. <article-title>Physician perspective on idiopathic hypersomnia: awareness, diagnosis, and impact on patients [poster 156]</article-title>. <conf-name>Presented at: Annual Meeting of the Associated Professional Sleep Societies</conf-name>; <conf-loc>Charlotte, NC</conf-loc>; <year>2022</year>.</mixed-citation>
      </ref>
      <ref id="cit0034">
        <label>34.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ohayon</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Thorpy</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Carls</surname>
<given-names>G</given-names></string-name>, et al. <article-title>The Nexus Narcolepsy Registry: methodology, study population characteristics, and patterns and predictors of narcolepsy diagnosis</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2021</year>;<volume>84</volume>:<fpage>405</fpage>–<lpage>414</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2021.06.008</pub-id><pub-id pub-id-type="pmid">34304148</pub-id></mixed-citation>
      </ref>
      <ref id="cit0035">
        <label>35.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lammers</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Bassetti</surname>
<given-names>CLA</given-names></string-name>, <string-name><surname>Dolenc-Groselj</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Diagnosis of central disorders of hypersomnolence: a reappraisal by European experts</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2020</year>;<volume>52</volume>:<fpage>101306</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2020.101306</pub-id><pub-id pub-id-type="pmid">32311642</pub-id></mixed-citation>
      </ref>
      <ref id="cit0036">
        <label>36.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Poli</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Pizza</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Mignot</surname>
<given-names>E</given-names></string-name>, et al. <article-title>High prevalence of precocious puberty and obesity in childhood narcolepsy with cataplexy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2013</year>;<volume>36</volume>(<issue>2</issue>):<fpage>175</fpage>–<lpage>181</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.2366</pub-id><pub-id pub-id-type="pmid">23372264</pub-id></mixed-citation>
      </ref>
      <ref id="cit0037">
        <label>37.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Black</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Reaven</surname>
<given-names>NL</given-names></string-name>, <string-name><surname>Funk</surname>
<given-names>SE</given-names></string-name>, et al. <article-title>Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2017</year>;<volume>33</volume>:<fpage>13</fpage>–<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2016.04.004</pub-id><pub-id pub-id-type="pmid">28449892</pub-id></mixed-citation>
      </ref>
      <ref id="cit0038">
        <label>38.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ben-Joseph</surname>
<given-names>RH</given-names></string-name>, <string-name><surname>Saad</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Black</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2023</year>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsad161</pub-id></mixed-citation>
      </ref>
      <ref id="cit0039">
        <label>39.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Saad</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Prince</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Taylor</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Ben-Joseph</surname>
<given-names>RH</given-names></string-name>. <article-title>Characteristics of adults newly diagnosed with idiopathic hypersomnia in the United States</article-title>. <source><italic toggle="yes">Sleep Epidemiol</italic></source>. <year>2023</year>. <month>18 July Online Ahead of Print</month>. doi:<pub-id pub-id-type="doi">10.1016/j.sleepe.2023.100059</pub-id></mixed-citation>
      </ref>
      <ref id="cit0040">
        <label>40.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Miglis</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Schneider</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Cheung</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Trotti</surname>
<given-names>LM</given-names></string-name>. <article-title>Frequency and severity of autonomic symptoms in idiopathic hypersomnia</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2020</year>;<volume>16</volume>(<issue>5</issue>):<fpage>749</fpage>–<lpage>756</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.8344</pub-id><pub-id pub-id-type="pmid">32039754</pub-id></mixed-citation>
      </ref>
      <ref id="cit0041">
        <label>41.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Vernet</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Leu-Semenescu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Buzare</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Arnulf</surname>
<given-names>I</given-names></string-name>. <article-title>Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepiness</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2010</year>;<volume>19</volume>(<issue>4</issue>):<fpage>525</fpage>–<lpage>534</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2869.2010.00824.x</pub-id><pub-id pub-id-type="pmid">20408941</pub-id></mixed-citation>
      </ref>
      <ref id="cit0042">
        <label>42.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Arnulf</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Leu-Semenescu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Dodet</surname>
<given-names>P</given-names></string-name>. <article-title>Precision medicine for idiopathic hypersomnia</article-title>. <source><italic toggle="yes">Sleep Med Clin</italic></source>. <year>2019</year>;<volume>14</volume>(<issue>3</issue>):<fpage>333</fpage>–<lpage>350</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsmc.2019.05.007</pub-id><pub-id pub-id-type="pmid">31375202</pub-id></mixed-citation>
      </ref>
      <ref id="cit0043">
        <label>43.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Maski</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Mignot</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Plazzi</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>. <article-title>Disrupted nighttime sleep and sleep instability in narcolepsy</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2022</year>;<volume>18</volume>(<issue>1</issue>):<fpage>289</fpage>–<lpage>304</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.9638</pub-id><pub-id pub-id-type="pmid">34463249</pub-id></mixed-citation>
      </ref>
      <ref id="cit0044">
        <label>44.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Schneider</surname>
<given-names>LD</given-names></string-name>, <string-name><surname>Stevens</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Husain</surname>
<given-names>AM</given-names></string-name>, et al. <article-title>Symptom severity and treatment satisfaction in patients with idiopathic hypersomnia: the real world idiopathic hypersomnia outcomes study (ARISE)</article-title>. <source><italic toggle="yes">Nat Sci Sleep</italic></source>. <year>2023</year>;<volume>15</volume>:<fpage>89</fpage>–<lpage>101</lpage>. doi:<pub-id pub-id-type="doi">10.2147/NSS.S386021</pub-id><pub-id pub-id-type="pmid">36937782</pub-id></mixed-citation>
      </ref>
      <ref id="cit0045">
        <label>45.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ong</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Dawson</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Mundt</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Moore</surname>
<given-names>C</given-names></string-name>. <article-title>Developing a cognitive behavioral therapy for hypersomnia using telehealth: a feasibility study</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2020</year>;<volume>16</volume>(<issue>12</issue>):<fpage>2047</fpage>–<lpage>2062</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.8750</pub-id><pub-id pub-id-type="pmid">32804069</pub-id></mixed-citation>
      </ref>
      <ref id="cit0046">
        <label>46.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kornum</surname>
<given-names>BR</given-names></string-name>, <string-name><surname>Knudsen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ollila</surname>
<given-names>HM</given-names></string-name>, et al. <article-title>Narcolepsy</article-title>. <source><italic toggle="yes">Nat Rev Dis Primers</italic></source>. <year>2017</year>;<volume>3</volume>:<fpage>16100</fpage>. doi:<pub-id pub-id-type="doi">10.1038/nrdp.2016.100</pub-id><pub-id pub-id-type="pmid">28179647</pub-id></mixed-citation>
      </ref>
      <ref id="cit0047">
        <label>47.</label>
        <mixed-citation publication-type="webpage"><article-title>Avadel pharmaceuticals announces final FDA approval of LUMRYZ™ (sodium oxybate) for extended-release oral suspension as the first and only once-at-bedtime oxybate for cataplexy or excessive daytime sleepiness in adults with narcolepsy [press release]</article-title>; <year>2023</year>. <comment>Available from</comment>: <ext-link xlink:href="https://investors.avadel.com/news-releases/news-release-details/avadel-pharmaceuticals-announces-final-fda-approval-lumryztm" ext-link-type="uri">https://investors.avadel.com/news-releases/news-release-details/avadel-pharmaceuticals-announces-final-fda-approval-lumryztm</ext-link>. <date-in-citation>Accessed <month>May</month>
<day>1</day>, 2023</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="cit0048">
        <label>48.</label>
        <mixed-citation publication-type="book"><source><italic toggle="yes">Lumryz<sup>TM</sup> (Sodium Oxybate) for Extended-Release Oral Solution, CIII [Prescribing Information]</italic></source>. <publisher-loc>Chesterfield, MO</publisher-loc>: <publisher-name>Avadel CNS Pharmaceuticals</publisher-name>; <year>2023</year>.</mixed-citation>
      </ref>
      <ref id="cit0049">
        <label>49.</label>
        <mixed-citation publication-type="webpage"><collab>European Medicines Agency</collab>. <article-title>Modafinil</article-title>; <year>2011</year>. <comment>Available from</comment>: <ext-link xlink:href="https://www.ema.europa.eu/en/medicines/human/referrals/modafinil#:~:text=Looking" ext-link-type="uri">https://www.ema.europa.eu/en/medicines/human/referrals/modafinil#:~:text=Looking</ext-link>. <date-in-citation>Accessed <month>February</month>
<day>2</day>, 2022</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="cit0050">
        <label>50.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Maski</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Trotti</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Kotagal</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2021</year>;<volume>17</volume>(<issue>9</issue>):<fpage>1881</fpage>–<lpage>1893</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.9328</pub-id><pub-id pub-id-type="pmid">34743789</pub-id></mixed-citation>
      </ref>
      <ref id="cit0051">
        <label>51.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lopez</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Arnulf</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Drouot</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Lecendreux</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>. <article-title>French consensus. Management of patients with hypersomnia: which strategy?</article-title>
<source><italic toggle="yes">Rev Neurol</italic></source>. <year>2017</year>;<volume>173</volume>(<issue>1–2</issue>):<fpage>8</fpage>–<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neurol.2016.09.018</pub-id><pub-id pub-id-type="pmid">27865546</pub-id></mixed-citation>
      </ref>
      <ref id="cit0052">
        <label>52.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bogan</surname>
<given-names>RK</given-names></string-name>, <string-name><surname>Thorpy</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2021</year>;<volume>44</volume>(<issue>3</issue>):<fpage>zsaa206</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsaa206</pub-id><pub-id pub-id-type="pmid">33184650</pub-id></mixed-citation>
      </ref>
      <ref id="cit0053">
        <label>53.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Arnulf</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Foldvary-Schaefer</surname>
<given-names>N</given-names></string-name>, et al. <article-title>Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study</article-title>. <source><italic toggle="yes">Lancet Neurol</italic></source>. <year>2022</year>;<volume>21</volume>(<issue>1</issue>):<fpage>53</fpage>–<lpage>65</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(21)00368-9</pub-id><pub-id pub-id-type="pmid">34942138</pub-id></mixed-citation>
      </ref>
      <ref id="cit0054">
        <label>54.</label>
        <mixed-citation publication-type="book"><source><italic toggle="yes">Xyrem<sup>®</sup> (Sodium Oxybate) Oral Solution, CIII [Prescribing Information]</italic></source>. <publisher-loc>Palo Alto, CA</publisher-loc>: <publisher-name>Jazz Pharmaceuticals, Inc.</publisher-name>; <year>2023</year>.</mixed-citation>
      </ref>
      <ref id="cit0055">
        <label>55.</label>
        <mixed-citation publication-type="book"><collab>World Health Organization</collab>. <source><italic toggle="yes">Guideline: Sodium Intake for Adults and Children</italic></source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2012</year>.</mixed-citation>
      </ref>
      <ref id="cit0056">
        <label>56.</label>
        <mixed-citation publication-type="book"><collab>Institute of Medicine</collab>. <source><italic toggle="yes">Sodium Intake in Populations: Assessment of Evidence</italic></source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>; <year>2013</year>.</mixed-citation>
      </ref>
      <ref id="cit0057">
        <label>57.</label>
        <mixed-citation publication-type="book"><collab>U.S. Department of Health and Human Services, U.S. Department of Agriculture</collab>. <source><italic toggle="yes">2015–2020 Dietary Guidelines for Americans</italic></source>. <edition>8th</edition> ed. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>United States Department of Agriculture</publisher-name>; <year>2015</year>.</mixed-citation>
      </ref>
      <ref id="cit0058">
        <label>58.</label>
        <mixed-citation publication-type="webpage"><collab>US Food and Drug Administration</collab>. <article-title>Voluntary sodium reduction goals: target mean and upper bound concentrations for sodium in commercially processed, packaged, and prepared foods: guidance for industry</article-title>. <year>2021</year>. <comment>Available from</comment>: <ext-link xlink:href="https://www.fda.gov/media/98264/download" ext-link-type="uri">https://www.fda.gov/media/98264/download</ext-link>. <date-in-citation>Accessed <month>December</month>
<day>8</day>, 2021</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="cit0059">
        <label>59.</label>
        <mixed-citation publication-type="book"><collab>National Academies of Sciences Engineering and Medicine</collab>. <source><italic toggle="yes">Dietary Reference Intakes for Sodium and Potassium</italic></source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>; <year>2019</year>.</mixed-citation>
      </ref>
      <ref id="cit0060">
        <label>60.</label>
        <mixed-citation publication-type="book"><collab>United States Department of Agriculture</collab>. <article-title>Scientific report of the 2015 dietary guidelines advisory committee</article-title>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>United States Department of Health and Human Services; United States Department of Agriculture</publisher-name>; <year>2015</year>.</mixed-citation>
      </ref>
      <ref id="cit0061">
        <label>61.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Quader</surname>
<given-names>ZS</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Gillespie</surname>
<given-names>C</given-names></string-name>, et al. <article-title>Sodium intake among persons aged ≥2 years - United States, 2013–2014</article-title>. <source><italic toggle="yes">MMWR Morb Mortal Wkly Rep</italic></source>. <year>2017</year>;<volume>66</volume>(<issue>12</issue>):<fpage>238</fpage>–<lpage>324</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.mm6612a3</pub-id></mixed-citation>
      </ref>
      <ref id="cit0062">
        <label>62.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Strazzullo</surname>
<given-names>P</given-names></string-name>, <string-name><surname>D’Elia</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Kandala</surname>
<given-names>NB</given-names></string-name>, <string-name><surname>Cappuccio</surname>
<given-names>FP</given-names></string-name>. <article-title>Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2009</year>;<volume>339</volume>:<fpage>b4567</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.b4567</pub-id><pub-id pub-id-type="pmid">19934192</pub-id></mixed-citation>
      </ref>
      <ref id="cit0063">
        <label>63.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ma</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>He</surname>
<given-names>FJ</given-names></string-name>, <string-name><surname>Sun</surname>
<given-names>Q</given-names></string-name>, et al. <article-title>24-Hour urinary sodium and potassium excretion and cardiovascular risk</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2022</year>;<volume>386</volume>(<issue>3</issue>):<fpage>252</fpage>–<lpage>263</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2109794</pub-id><pub-id pub-id-type="pmid">34767706</pub-id></mixed-citation>
      </ref>
      <ref id="cit0064">
        <label>64.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gardener</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Rundek</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Wright</surname>
<given-names>CB</given-names></string-name>, <string-name><surname>Elkind</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Sacco</surname>
<given-names>RL</given-names></string-name>. <article-title>Dietary sodium and risk of stroke in the Northern Manhattan study</article-title>. <source><italic toggle="yes">Stroke</italic></source>. <year>2012</year>;<volume>43</volume>(<issue>5</issue>):<fpage>1200</fpage>–<lpage>1205</lpage>. doi:<pub-id pub-id-type="doi">10.1161/STROKEAHA.111.641043</pub-id><pub-id pub-id-type="pmid">22499576</pub-id></mixed-citation>
      </ref>
      <ref id="cit0065">
        <label>65.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Mozaffarian</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Fahimi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Singh</surname>
<given-names>GM</given-names></string-name>, et al. <article-title>Global sodium consumption and death from cardiovascular causes</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2014</year>;<volume>371</volume>(<issue>7</issue>):<fpage>624</fpage>–<lpage>634</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1304127</pub-id><pub-id pub-id-type="pmid">25119608</pub-id></mixed-citation>
      </ref>
      <ref id="cit0066">
        <label>66.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chen</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Jenkins</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zomorodi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Skowronski</surname>
<given-names>R</given-names></string-name>. <article-title>Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in 2 open-label, randomized, crossover studies</article-title>. <source><italic toggle="yes">Clin Transl Sci</italic></source>. <year>2021</year>;<volume>14</volume>(<issue>6</issue>):<fpage>2278</fpage>–<lpage>2287</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cts.13087</pub-id><pub-id pub-id-type="pmid">34121333</pub-id></mixed-citation>
      </ref>
      <ref id="cit0067">
        <label>67.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Thannickal</surname>
<given-names>TC</given-names></string-name>, <string-name><surname>Nienhuis</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Siegel</surname>
<given-names>JM</given-names></string-name>. <article-title>Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2009</year>;<volume>32</volume>(<issue>8</issue>):<fpage>993</fpage>–<lpage>998</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/32.8.993</pub-id><pub-id pub-id-type="pmid">19725250</pub-id></mixed-citation>
      </ref>
      <ref id="cit0068">
        <label>68.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kamal</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>van Noorden</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Franzek</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Dijkstra</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>Loonen</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>De Jong</surname>
<given-names>CA</given-names></string-name>. <article-title>The neurobiological mechanisms of gamma-hydroxybutyrate dependence and withdrawal and their clinical relevance: a review</article-title>. <source><italic toggle="yes">Neuropsychobiology</italic></source>. <year>2016</year>;<volume>73</volume>(<issue>2</issue>):<fpage>65</fpage>–<lpage>80</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000443173</pub-id><pub-id pub-id-type="pmid">27003176</pub-id></mixed-citation>
      </ref>
      <ref id="cit0069">
        <label>69.</label>
        <mixed-citation publication-type="journal"><collab>U.S. Xyrem Multicenter Study Group</collab>. <article-title>A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2002</year>;<volume>25</volume>(<issue>1</issue>):<fpage>42</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">11833860</pub-id></mixed-citation>
      </ref>
      <ref id="cit0070">
        <label>70.</label>
        <mixed-citation publication-type="journal"><collab>U.S. Xyrem Multicenter Study Group</collab>. <article-title>Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2004</year>;<volume>5</volume>(<issue>2</issue>):<fpage>119</fpage>–<lpage>123</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2003.11.002</pub-id><pub-id pub-id-type="pmid">15033130</pub-id></mixed-citation>
      </ref>
      <ref id="cit0071">
        <label>71.</label>
        <mixed-citation publication-type="journal"><collab>U.S. Xyrem Multicenter Study Group</collab>. <article-title>A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2003</year>;<volume>26</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">12627729</pub-id></mixed-citation>
      </ref>
      <ref id="cit0072">
        <label>72.</label>
        <mixed-citation publication-type="journal"><collab>Xyrem International Study Group</collab>. <article-title>A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2005</year>;<volume>1</volume>(<issue>4</issue>):<fpage>391</fpage>–<lpage>397</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.26368</pub-id><pub-id pub-id-type="pmid">17564408</pub-id></mixed-citation>
      </ref>
      <ref id="cit0073">
        <label>73.</label>
        <mixed-citation publication-type="journal"><collab>Xyrem International Study Group</collab>. <article-title>Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2005</year>;<volume>6</volume>(<issue>5</issue>):<fpage>415</fpage>–<lpage>421</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2005.03.010</pub-id><pub-id pub-id-type="pmid">16099718</pub-id></mixed-citation>
      </ref>
      <ref id="cit0074">
        <label>74.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Black</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Houghton</surname>
<given-names>WC</given-names></string-name>. <article-title>Sodium oxybate improves excessive daytime sleepiness in narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2006</year>;<volume>29</volume>(<issue>7</issue>):<fpage>939</fpage>–<lpage>946</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/29.7.939</pub-id><pub-id pub-id-type="pmid">16895262</pub-id></mixed-citation>
      </ref>
      <ref id="cit0075">
        <label>75.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Plazzi</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ruoff</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lecendreux</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation</article-title>. <source><italic toggle="yes">Lancet Child Adolesc Health</italic></source>. <year>2018</year>;<volume>2</volume>(<issue>7</issue>):<fpage>483</fpage>–<lpage>494</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2352-4642(18)30133-0</pub-id><pub-id pub-id-type="pmid">30169321</pub-id></mixed-citation>
      </ref>
      <ref id="cit0076">
        <label>76.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Šonka</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Bogan</surname>
<given-names>RK</given-names></string-name>, et al. <article-title>Changes in cataplexy frequency in a clinical trial of lower-sodium oxybate with taper and discontinuation of other anticataplectic medications</article-title>. <source><italic toggle="yes">CNS Drugs</italic></source>. <year>2022</year>;<volume>36</volume>:<fpage>633</fpage>–<lpage>647</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40263-022-00926-0</pub-id><pub-id pub-id-type="pmid">35635687</pub-id></mixed-citation>
      </ref>
      <ref id="cit0077">
        <label>77.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Black</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Pardi</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hornfeldt</surname>
<given-names>CS</given-names></string-name>, <string-name><surname>Inhaber</surname>
<given-names>N</given-names></string-name>. <article-title>The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2009</year>;<volume>10</volume>(<issue>8</issue>):<fpage>829</fpage>–<lpage>835</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2009.05.004</pub-id><pub-id pub-id-type="pmid">19616998</pub-id></mixed-citation>
      </ref>
      <ref id="cit0078">
        <label>78.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Roth</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Guinta</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Alvarez-Horine</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Dynin</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Black</surname>
<given-names>J</given-names></string-name>. <article-title>Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2017</year>;<volume>40</volume>:<fpage>53</fpage>–<lpage>57</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2017.07.030</pub-id><pub-id pub-id-type="pmid">29221779</pub-id></mixed-citation>
      </ref>
      <ref id="cit0079">
        <label>79.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Black</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Pardi</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hornfeldt</surname>
<given-names>CS</given-names></string-name>, <string-name><surname>Inhaber</surname>
<given-names>N</given-names></string-name>. <article-title>The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2010</year>;<volume>6</volume>(<issue>6</issue>):<fpage>596</fpage>–<lpage>602</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.27994</pub-id><pub-id pub-id-type="pmid">21206549</pub-id></mixed-citation>
      </ref>
      <ref id="cit0080">
        <label>80.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Husain</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Bujanover</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ryan</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Scheckner</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Black</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Profant</surname>
<given-names>J</given-names></string-name>. <article-title>Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2020</year>;<volume>16</volume>(<issue>9</issue>):<fpage>1469</fpage>–<lpage>1474</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.8530</pub-id><pub-id pub-id-type="pmid">32356515</pub-id></mixed-citation>
      </ref>
      <ref id="cit0081">
        <label>81.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bogan</surname>
<given-names>RK</given-names></string-name>, <string-name><surname>Foldvary-Schaefer</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Skowronski</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Thorpy</surname>
<given-names>MJ</given-names></string-name>. <article-title>Long-term safety and tolerability during a clinical trial and open-label extension of lower-sodium oxybate in participants with narcolepsy with cataplexy</article-title>. <source><italic toggle="yes">CNS Drugs</italic></source>. <year>2023</year>;<volume>37</volume>(<issue>4</issue>):<fpage>323</fpage>–<lpage>335</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40263-023-00992-y</pub-id><pub-id pub-id-type="pmid">36947322</pub-id></mixed-citation>
      </ref>
      <ref id="cit0082">
        <label>82.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Thorpy</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Arnulf</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Foldvary-Schaefer</surname>
<given-names>N</given-names></string-name>, et al. <article-title>Efficacy and safety of lower-sodium oxybate in an open-label titration period of a phase 3 clinical study in adults with idiopathic hypersomnia</article-title>. <source><italic toggle="yes">Nat Sci Sleep</italic></source>. <year>2022</year>;<volume>14</volume>:<fpage>1901</fpage>–<lpage>1917</lpage>. doi:<pub-id pub-id-type="doi">10.2147/NSS.S369122</pub-id><pub-id pub-id-type="pmid">36320423</pub-id></mixed-citation>
      </ref>
      <ref id="cit0083">
        <label>83.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Morse</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Arnulf</surname>
<given-names>I</given-names></string-name>, et al. <article-title>Long-term efficacy and safety of lower-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2023</year>. <month>July 6 Online Ahead of Print.</month> doi:<pub-id pub-id-type="doi">10.5664/jcsm.10698</pub-id></mixed-citation>
      </ref>
      <ref id="cit0084">
        <label>84.</label>
        <mixed-citation publication-type="confproc"><string-name><surname>Leary</surname>
<given-names>EB</given-names></string-name>, <string-name><surname>Pfister</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Fuller</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Macfadden</surname>
<given-names>W</given-names></string-name>. <article-title>Effectiveness and optimization of low-sodium oxybate in participants with narcolepsy switching from sodium oxybate (SEGUE) [poster 324]</article-title>. <conf-name>Presented at: Annual Meeting of the Associated Professional Sleep Societies</conf-name>; <conf-loc>Indianapolis, IN</conf-loc>; <year>2023</year>.</mixed-citation>
      </ref>
      <ref id="cit0085">
        <label>85.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Philip</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Chaufton</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Taillard</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2014</year>;<volume>37</volume>(<issue>3</issue>):<fpage>483</fpage>–<lpage>487</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.3480</pub-id><pub-id pub-id-type="pmid">24587570</pub-id></mixed-citation>
      </ref>
      <ref id="cit0086">
        <label>86.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Sagaspe</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Micoulaud-Franchi</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Coste</surname>
<given-names>O</given-names></string-name>, et al. <article-title>Maintenance of Wakefulness Test, real and simulated driving in patients with narcolepsy/hypersomnia</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2019</year>;<volume>55</volume>:<fpage>1</fpage>–<lpage>5</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2018.02.009</pub-id><pub-id pub-id-type="pmid">30735912</pub-id></mixed-citation>
      </ref>
      <ref id="cit0087">
        <label>87.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Husain</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Ristanovic</surname>
<given-names>RK</given-names></string-name>, <string-name><surname>Bogan</surname>
<given-names>RK</given-names></string-name>. <article-title>Weight loss in narcolepsy patients treated with sodium oxybate</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2009</year>;<volume>10</volume>(<issue>6</issue>):<fpage>661</fpage>–<lpage>663</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2008.05.012</pub-id><pub-id pub-id-type="pmid">19014899</pub-id></mixed-citation>
      </ref>
      <ref id="cit0088">
        <label>88.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Schinkelshoek</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Smolders</surname>
<given-names>IM</given-names></string-name>, <string-name><surname>Donjacour</surname>
<given-names>CE</given-names></string-name>, et al. <article-title>Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2019</year>;<volume>28</volume>(<issue>3</issue>):<fpage>e12684</fpage>. doi:<pub-id pub-id-type="doi">10.1111/jsr.12684</pub-id><pub-id pub-id-type="pmid">29504180</pub-id></mixed-citation>
      </ref>
      <ref id="cit0089">
        <label>89.</label>
        <mixed-citation publication-type="confproc"><string-name><surname>Foldvary-Schaefer</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Skowronski</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Hickey</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Measey</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>. <article-title>Weight changes during treatment with lower-sodium oxybate in a phase 3 clinical study in patients with narcolepsy [poster 136]</article-title>. <conf-name>Presented at: Annual Meeting of the Associated Professional Sleep Societies</conf-name>; <conf-loc>Charlotte, NC</conf-loc>; <year>2022</year>.</mixed-citation>
      </ref>
      <ref id="cit0090">
        <label>90.</label>
        <mixed-citation publication-type="confproc"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chandler</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Hickey</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Steininger</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Foldvary-Schaefer</surname>
<given-names>N</given-names></string-name>. <article-title>Weight changes during treatment with lower-sodium oxybate in a phase 3 clinical study in patients with idiopathic hypersomnia [poster 132]</article-title>. <conf-name>Presented at: Annual Meeting of the Associated Professional Sleep Societies</conf-name>; <conf-loc>Charlotte, NC</conf-loc>; <year>2022</year>.</mixed-citation>
      </ref>
      <ref id="cit0091">
        <label>91.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Donjacour</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Aziz</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Overeem</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kalsbeek</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pijl</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Lammers</surname>
<given-names>GJ</given-names></string-name>. <article-title>Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2014</year>;<volume>37</volume>(<issue>4</issue>):<fpage>795</fpage>–<lpage>801</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.3592</pub-id><pub-id pub-id-type="pmid">24899766</pub-id></mixed-citation>
      </ref>
      <ref id="cit0092">
        <label>92.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Cohen</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mandrekar</surname>
<given-names>J</given-names></string-name>, <string-name><surname>St Louis</surname>
<given-names>EK</given-names></string-name>, <string-name><surname>Silber</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Kotagal</surname>
<given-names>S</given-names></string-name>. <article-title>Comorbidities in a community sample of narcolepsy</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2018</year>;<volume>43</volume>:<fpage>14</fpage>–<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2017.11.1125</pub-id><pub-id pub-id-type="pmid">29482805</pub-id></mixed-citation>
      </ref>
      <ref id="cit0093">
        <label>93.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Jaussent</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Krams</surname>
<given-names>B</given-names></string-name>, et al. <article-title>Non-dipping blood pressure profile in narcolepsy with cataplexy</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2012</year>;<volume>7</volume>(<issue>6</issue>):<fpage>e38977</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0038977</pub-id><pub-id pub-id-type="pmid">22768053</pub-id></mixed-citation>
      </ref>
      <ref id="cit0094">
        <label>94.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hermida</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Crespo</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Otero</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention</article-title>. <source><italic toggle="yes">Eur Heart J</italic></source>. <year>2018</year>;<volume>39</volume>(<issue>47</issue>):<fpage>4159</fpage>–<lpage>4171</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehy475</pub-id><pub-id pub-id-type="pmid">30107515</pub-id></mixed-citation>
      </ref>
      <ref id="cit0095">
        <label>95.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hozawa</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Inoue</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Ohkubo</surname>
<given-names>T</given-names></string-name>, et al. <article-title>Predictive value of ambulatory heart rate in the Japanese general population: the Ohasama study</article-title>. <source><italic toggle="yes">J Hypertens</italic></source>. <year>2008</year>;<volume>26</volume>(<issue>8</issue>):<fpage>1571</fpage>–<lpage>1576</lpage>. doi:<pub-id pub-id-type="doi">10.1097/HJH.0b013e3283041172</pub-id><pub-id pub-id-type="pmid">18622234</pub-id></mixed-citation>
      </ref>
      <ref id="cit0096">
        <label>96.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ohkubo</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hozawa</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Yamaguchi</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study</article-title>. <source><italic toggle="yes">J Hypertens</italic></source>. <year>2002</year>;<volume>20</volume>(<issue>11</issue>):<fpage>2183</fpage>–<lpage>2189</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00004872-200211000-00017</pub-id><pub-id pub-id-type="pmid">12409956</pub-id></mixed-citation>
      </ref>
      <ref id="cit0097">
        <label>97.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Grandner</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Jackson</surname>
<given-names>NJ</given-names></string-name>, <string-name><surname>Pak</surname>
<given-names>VM</given-names></string-name>, <string-name><surname>Gehrman</surname>
<given-names>PR</given-names></string-name>. <article-title>Sleep disturbance is associated with cardiovascular and metabolic disorders</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2012</year>;<volume>21</volume>(<issue>4</issue>):<fpage>427</fpage>–<lpage>433</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2869.2011.00990.x</pub-id><pub-id pub-id-type="pmid">22151079</pub-id></mixed-citation>
      </ref>
      <ref id="cit0098">
        <label>98.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bock</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Covassin</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Somers</surname>
<given-names>V</given-names></string-name>. <article-title>Excessive daytime sleepiness: an emerging marker of cardiovascular risk</article-title>. <source><italic toggle="yes">Heart</italic></source>. <year>2022</year>;<volume>108</volume>(<issue>22</issue>):<fpage>1761</fpage>–<lpage>1766</lpage>. doi:<pub-id pub-id-type="doi">10.1136/heartjnl-2021-319596</pub-id><pub-id pub-id-type="pmid">35102000</pub-id></mixed-citation>
      </ref>
      <ref id="cit0099">
        <label>99.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bigalke</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Shan</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Carter</surname>
<given-names>JR</given-names></string-name>. <article-title>Orexin, sleep, sympathetic neural activity, and cardiovascular function</article-title>. <source><italic toggle="yes">Hypertension</italic></source>. <year>2022</year>;<volume>79</volume>(<issue>12</issue>):<fpage>2643</fpage>–<lpage>2655</lpage>. doi:<pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.122.19796</pub-id><pub-id pub-id-type="pmid">36148653</pub-id></mixed-citation>
      </ref>
      <ref id="cit0100">
        <label>100.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jacobs</surname>
<given-names>DR</given-names> Jr</string-name>, <string-name><surname>Woo</surname>
<given-names>JG</given-names></string-name>, <string-name><surname>Sinaiko</surname>
<given-names>AR</given-names></string-name>, et al. <article-title>Childhood cardiovascular risk factors and adult cardiovascular events</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2022</year>;<volume>386</volume>(<issue>20</issue>):<fpage>1877</fpage>–<lpage>1888</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2109191</pub-id><pub-id pub-id-type="pmid">35373933</pub-id></mixed-citation>
      </ref>
      <ref id="cit0101">
        <label>101.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Aburto</surname>
<given-names>NJ</given-names></string-name>, <string-name><surname>Ziolkovska</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hooper</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Elliott</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Cappuccio</surname>
<given-names>FP</given-names></string-name>, <string-name><surname>Meerpohl</surname>
<given-names>JJ</given-names></string-name>. <article-title>Effect of lower sodium intake on health: systematic review and meta-analyses</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2013</year>;<volume>346</volume>:<fpage>f1326</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.f1326</pub-id><pub-id pub-id-type="pmid">23558163</pub-id></mixed-citation>
      </ref>
      <ref id="cit0102">
        <label>102.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bibbins-Domingo</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Chertow</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Coxson</surname>
<given-names>PG</given-names></string-name>, et al. <article-title>Projected effect of dietary salt reductions on future cardiovascular disease</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2010</year>;<volume>362</volume>(<issue>7</issue>):<fpage>590</fpage>–<lpage>599</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa0907355</pub-id><pub-id pub-id-type="pmid">20089957</pub-id></mixed-citation>
      </ref>
      <ref id="cit0103">
        <label>103.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Cook</surname>
<given-names>NR</given-names></string-name>, <string-name><surname>Cutler</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Obarzanek</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2007</year>;<volume>334</volume>(<issue>7599</issue>):<fpage>885</fpage>–<lpage>888</lpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.39147.604896.55</pub-id><pub-id pub-id-type="pmid">17449506</pub-id></mixed-citation>
      </ref>
      <ref id="cit0104">
        <label>104.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Whelton</surname>
<given-names>PK</given-names></string-name>, <string-name><surname>Appel</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Charleston</surname>
<given-names>J</given-names></string-name>, et al. <article-title>The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. results of the trials of hypertension prevention, phase I</article-title>. <source><italic toggle="yes">JAMA</italic></source>. <year>1992</year>;<volume>267</volume>(<issue>9</issue>):<fpage>1213</fpage>–<lpage>1220</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.1992.03480090061028</pub-id><pub-id pub-id-type="pmid">1586398</pub-id></mixed-citation>
      </ref>
      <ref id="cit0105">
        <label>105.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Whelton</surname>
<given-names>PK</given-names></string-name>, <string-name><surname>Appel</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Charleston</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure</article-title>. <source><italic toggle="yes">Arch Intern Med</italic></source>. <year>1997</year>;<volume>157</volume>(<issue>6</issue>):<fpage>657</fpage>–<lpage>667</lpage>.<pub-id pub-id-type="pmid">9080920</pub-id></mixed-citation>
      </ref>
      <ref id="cit0106">
        <label>106.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Sacks</surname>
<given-names>FM</given-names></string-name>, <string-name><surname>Svetkey</surname>
<given-names>LP</given-names></string-name>, <string-name><surname>Vollmer</surname>
<given-names>WM</given-names></string-name>, et al. <article-title>Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2001</year>;<volume>344</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM200101043440101</pub-id><pub-id pub-id-type="pmid">11136953</pub-id></mixed-citation>
      </ref>
      <ref id="cit0107">
        <label>107.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Neal</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Feng</surname>
<given-names>X</given-names></string-name>, et al. <article-title>Effect of salt substitution on cardiovascular events and death</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2021</year>;<volume>385</volume>(<issue>12</issue>):<fpage>1067</fpage>–<lpage>1077</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2105675</pub-id><pub-id pub-id-type="pmid">34459569</pub-id></mixed-citation>
      </ref>
      <ref id="cit0108">
        <label>108.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zeng</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Rosenberg</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>X</given-names></string-name>, et al. <article-title>Sodium-containing Acetaminophen and cardiovascular outcomes in individuals with and without hypertension</article-title>. <source><italic toggle="yes">Eur Heart J</italic></source>. <year>2022</year>;<volume>43</volume>(<issue>18</issue>):<fpage>1743</fpage>–<lpage>1755</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehac059</pub-id><pub-id pub-id-type="pmid">35201347</pub-id></mixed-citation>
      </ref>
      <ref id="cit0109">
        <label>109.</label>
        <mixed-citation publication-type="journal"><string-name><surname>George</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Majeed</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Mackenzie</surname>
<given-names>IS</given-names></string-name>, <string-name><surname>Macdonald</surname>
<given-names>TM</given-names></string-name>, <string-name><surname>Wei</surname>
<given-names>L</given-names></string-name>. <article-title>Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2013</year>;<volume>347</volume>:<fpage>f6954</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.f6954</pub-id><pub-id pub-id-type="pmid">24284017</pub-id></mixed-citation>
      </ref>
      <ref id="cit0110">
        <label>110.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Benitez-Camps</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Morros Padros</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Pera-Pujadas</surname>
<given-names>H</given-names></string-name>, et al. <article-title>Effect of effervescent paracetamol on blood pressure: a crossover randomized clinical trial</article-title>. <source><italic toggle="yes">J Hypertens</italic></source>. <year>2018</year>;<volume>36</volume>(<issue>8</issue>):<fpage>1656</fpage>–<lpage>1662</lpage>. doi:<pub-id pub-id-type="doi">10.1097/HJH.0000000000001733</pub-id><pub-id pub-id-type="pmid">29570512</pub-id></mixed-citation>
      </ref>
      <ref id="cit0111">
        <label>111.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ubeda</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Llopico</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sanchez</surname>
<given-names>MT</given-names></string-name>. <article-title>Blood pressure reduction in hypertensive patients after withdrawal of effervescent medication</article-title>. <source><italic toggle="yes">Pharmacoepidemiol Drug Saf</italic></source>. <year>2009</year>;<volume>18</volume>(<issue>5</issue>):<fpage>417</fpage>–<lpage>419</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pds.1701</pub-id><pub-id pub-id-type="pmid">19248080</pub-id></mixed-citation>
      </ref>
      <ref id="cit0112">
        <label>112.</label>
        <mixed-citation publication-type="webpage"><article-title>Clinical superiority findings</article-title>; <year>2021</year>. <comment>Available from</comment>: <ext-link xlink:href="https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings" ext-link-type="uri">https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings</ext-link>. <date-in-citation>Accessed <month>July</month>
<day>9</day>, 2021</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="cit0113">
        <label>113.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bosco</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lopez</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Barateau</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2018</year>;<volume>90</volume>(<issue>6</issue>):<fpage>e479</fpage>–<lpage>e491</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000004911</pub-id><pub-id pub-id-type="pmid">29321233</pub-id></mixed-citation>
      </ref>
      <ref id="cit0114">
        <label>114.</label>
        <mixed-citation publication-type="webpage"><article-title>Life’s Essential 8</article-title>; <year>2022</year>. <comment>Available from</comment>: <ext-link xlink:href="https://www.heart.org/en/healthy-living/healthy-lifestyle/lifes-essential-8" ext-link-type="uri">https://www.heart.org/en/healthy-living/healthy-lifestyle/lifes-essential-8</ext-link>. <date-in-citation>Accessed <month>January</month>
<day>16</day>, 2023</date-in-citation>.</mixed-citation>
      </ref>
      <ref id="cit0115">
        <label>115.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Strunc</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Black</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lillaney</surname>
<given-names>P</given-names></string-name>, et al. <article-title>The Xyrem(<sup>®</sup>) (sodium oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: results from 2016 to 2017</article-title>. <source><italic toggle="yes">Drugs Real World Outcomes</italic></source>. <year>2021</year>;<volume>8</volume>(<issue>1</issue>):<fpage>15</fpage>–<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40801-020-00223-6</pub-id><pub-id pub-id-type="pmid">33439474</pub-id></mixed-citation>
      </ref>
      <ref id="cit0116">
        <label>116.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Molina</surname>
<given-names>BSG</given-names></string-name>, <string-name><surname>Kipp</surname>
<given-names>HL</given-names></string-name>, <string-name><surname>Joseph</surname>
<given-names>HM</given-names></string-name>, et al. <article-title>Stimulant diversion risk among college students treated for ADHD: primary care provider prevention training</article-title>. <source><italic toggle="yes">Acad Pediatr</italic></source>. <year>2020</year>;<volume>20</volume>(<issue>1</issue>):<fpage>119</fpage>–<lpage>127</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.acap.2019.06.002</pub-id><pub-id pub-id-type="pmid">31185307</pub-id></mixed-citation>
      </ref>
      <ref id="cit0117">
        <label>117.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Boucetta</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zadra</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Altered regional cerebral blood flow in idiopathic hypersomnia</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2017</year>;<volume>40</volume>(<issue>10</issue>). doi:<pub-id pub-id-type="doi">10.1093/sleep/zsx140</pub-id></mixed-citation>
      </ref>
      <ref id="cit0118">
        <label>118.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Pomares</surname>
<given-names>FB</given-names></string-name>, <string-name><surname>Boucetta</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lachapelle</surname>
<given-names>F</given-names></string-name>, et al. <article-title>Beyond sleepy: structural and functional changes of the default-mode network in idiopathic hypersomnia</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2019</year>;<volume>42</volume>(<issue>11</issue>). doi:<pub-id pub-id-type="doi">10.1093/sleep/zsz156</pub-id></mixed-citation>
      </ref>
      <ref id="cit0119">
        <label>119.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Evangelista</surname>
<given-names>E</given-names></string-name>, <string-name><surname>de Verbizier</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Barateau</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Peigneux</surname>
<given-names>P</given-names></string-name>. <article-title>[18F]Fludeoxyglucose-positron emission tomography evidence for cerebral hypermetabolism in the awake state in narcolepsy and idiopathic hypersomnia</article-title>. <source><italic toggle="yes">Front Neurol</italic></source>. <year>2017</year>;<volume>8</volume>:<fpage>350</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2017.00350</pub-id><pub-id pub-id-type="pmid">28775709</pub-id></mixed-citation>
      </ref>
      <ref id="cit0120">
        <label>120.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Scherfler</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Frauscher</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Schocke</surname>
<given-names>M</given-names></string-name>, et al. <article-title>White and gray matter abnormalities in narcolepsy with cataplexy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2012</year>;<volume>35</volume>(<issue>3</issue>):<fpage>345</fpage>–<lpage>351</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.1692</pub-id><pub-id pub-id-type="pmid">22379240</pub-id></mixed-citation>
      </ref>
      <ref id="cit0121">
        <label>121.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Huang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lyu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>X</given-names></string-name>. <article-title>Structural and functional brain alterations in obstructive sleep apnea: a multimodal meta-analysis</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2019</year>;<volume>54</volume>:<fpage>195</fpage>–<lpage>204</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2018.09.025</pub-id><pub-id pub-id-type="pmid">30580194</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
